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ABSTRACT 
 
Summary 
 
Diabetes Mellitus (DM) is one of the most important causes of vision loss 
and decrease of quality of life worldwide. It presents a large number of 
complications in its development. One of the most important complications 
is the Diabetic Retinopathy (RD). At present, the DM is considered a 
pandemic, since its prevalence does not stop increasing. 
 
DR is a growing ocular pathology and a cause of blindness worldwide with a 
prevalence of 34.6%. People with DR often do not realize changes in their 
vision during the early stages of the disease, but as the pathology progresses, 
it causes significant loss of vision and even blindness. Early diagnosis is, 
therefore, essential to promote good visual prognosis and prevent blindness 
caused by this disease. 
 
In this context, we propose a study about the relationship between plasma 
concentrations of folic acid (FA), vitamin B12, homocysteine (Hcys), total 
protein, C reactive protein (CRP), oxidative stress markers 
(malondialdehyde (MDA), glutathione Peroxidase (GPx), total antioxidant 
status (TAS) and the expression of certain genes related to these molecules 
in type 2 diabetic patients (DM2) and to analyse their correlation with the 
presentation and progression of DR in a Mediterranean population. 
 
For this, we carried out a multicentre epidemiological study of cases and 
controls that included 81 subjects, 49 with DM2 (14 +DR, 35 -DR) and 32 
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controls. The concentrations of the aforementioned molecules were 
determined and the gene expression was analysed. The data obtained were 
processed using the IBM SPSS for Windows v22.0. 
 
We observed significantly higher concentrations of CRP, Hcys, MDA and 
GPx and a significantly lower TAS in the DM2-DR and DM2+DR groups 
compared to the control group (CTRL) (p<0.05). Considering gene 
expression, we observed a lower expression of SLC23A2 and a greater 
expression of MMP9 in the DM2-DR and DM2+DR groups compared to the 
CTRL (p <0.05). The TP53 gene expression was only significantly higher 
between DM2+DR and the CTRL (p<0.05). 
 
Consequently, genes related to apoptosis (TP53) and extracellular matrix 
integrity (MMP9) could be considered as markers of susceptibility to the 
development and progression of DR. As well as the SLC232A2 gene 
(ascorbic acid transporter) may be considered as a protector of the risk of 
suffering or progressing the retinopathy in DM2 patients. 
 
 
 
 
 
 
 
 
 
 
Key words: diabetes mellitus, diabetic retinopathy, genetics, gene 
expression, oxidative stress, vitamin B12, homocysteine.  
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Resumen 
 
La Diabetes Mellitus (DM) constituye una de las causas más importantes de 
pérdida de visión y de la calidad de vida relacionada con la visión en todo el 
mundo, puesto que presenta un gran número de complicaciones en su 
desarrollo, siendo una de las más importantes la retinopatía diabética (RD). 
En la actualidad la DM se considera una pandemia, puesto que su 
prevalencia no deja de aumentar. 
 
La RD es una patología ocular en auge, causa de ceguera en todo el mundo 
con una prevalencia del 34,6%. Las personas con RD a menudo no se dan 
cuenta de los cambios en su visión durante las primeras etapas de la 
enfermedad  pero, a medida que avanza, causa una pérdida importante de 
visión e incluso ceguera. El diagnóstico precoz es esencial para favorecer el 
buen pronóstico visual y poder prevenir la ceguera producida por esta 
enfermedad. 
 
En este contexto, planteamos un estudio con el objetivo de establecer la 
relación entre las concentraciones plasmáticas de ácido fólico, vitamina B12, 
homocisteína (Hcys), proteína total, proteína C reativa (PCR), marcadores 
de estrés oxidativo (malonildialdehído – MDA, glutation peroxidasa – GPx, 
estado antioxidante total – EAT) y la expresión de ciertos genes 
relacionados con dichas moléculas, en pacientes diabéticos tipo 2 (DM2), y 
analizar su correlación con la presentación y progresión de la RD en una 
población mediterránea. 
 
Para ello, llevamos a cabo un estudio epidemiológico multicéntrico de casos 
y controles que incluyó 81 sujetos, 49 con DM2 (14 +RD, 35 –RD) y 32 
 
 
8 
 
controles. Se determinaron las concentraciones de las moléculas antes 
mencionadas y se analizó la expresión de los genes. Los datos obtenidos 
fueron procesados mediante el programa IBM SPSS para Windows v22.0. 
Observamos una concentración significativamente superior de PCR, Hcys, 
MDA y GPx y un EAT significativamente inferior en los grupos DM2-RD y 
DM2+RD respecto al grupo control (p<0.05). En cuanto a la expresión de 
genes, observamos una menor expresión de SLC23A2 y una mayor 
expresión de MMP9 en los grupos DM2-RD y DM2+RD respecto al grupo 
control (p<0.05). La expresión del gen TP53 sólo fue significativamente 
superior entre DM2+DR y el grupo control (p<0.05). 
 
Por tanto, los genes relacionados con apoptosis (TP53) e integridad de la 
matriz extracelular  (MMP9) podrían ser considerados como marcadores de 
susceptibilidad al desarrollo y progresión de la RD. Así como el gen  
SLC232A2 (transportador del ácido ascórbico) puede considerarse como 
protector del riesgo de padecer o progresar en la retinopatía en pacientes 
DM2. 
 
 
 
 
 
 
 
 
 
Palabras clave: diabetes mellitus, retinopatía diabética, genética, expresión 
genética, estrés oxidativo, vitamina B12, homocisteina. 
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INTRODUCTION 
 
 
1. About diabetes 
Diabetes is a collection of names for different diseases. Diabetes Mellitus 
(DM) indicates higher levels of glucose in the blood system. The root of the 
pathogenic mechanisms is different due to which different type of diabetes 
we refer too. There are many different types of DM, which have totally 
different causes, however type 2 (DM2) is the most common type of the 
disease. Therefore, finding proper diagnosis of the disease requires adequate 
type classification and thereafter careful treatment.  
 
The DM is increasing continuously in the world, specifically DM2, which 
shows pertinence in our modern living due to lower physical activity, and 
higher body weights, both in adults and in children (1). Increasing 
prevalence worldwide demands more action on DM prevention and 
management, with careful planning within the healthcare and the 
organizations behind it. Although it is not only a matter of a good healthcare 
system, yet also the modern western lifestyle must act for a more preventive 
lifestyle.  
 
Despite all modernized and refined drugs and treatments of the disease, 
complications in lingering patients are a wide problem. As an example, it is 
worth mentioning that, DM is the most common reason for severe poor 
vision in working adults in the western world and diabetes or pre-diabetes 
occur in most cases of myocardial infarctions (2). Notwithstanding intensive 
research behind the risk factors and the pathogenic mechanisms of this 
disease, there is still no exclusive medication or treatments that could 
specifically prevent it. 
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2. History 
The disease is first time described in an Egyptian papyrus roll (Figure 1) 
from 1550 b.c., in the so called “Papyrus Ebers” describing a polyuria 
condition (3). 
(Figure 1) Papyrus and Ostraca Collection of the University Library Leipzig. 
Source:http://www.organapapyrologica.net/content/members_leipzig.xml;jsessionid=7839B01E6F24794
0F893D43993AEB892;jsessionid=7839B01E6F247940F893D43993AEB892?XSL.lastPage.SESSION=/
content/members_leipzig.xml&lang=en 
 
Around 500 b.c. an Indian physician called Sushruta was the first who 
described the two types of DM, differentiating between those cases in young 
people, which caused death, and others in adults (4). 
(Figure 2) Sushruta statue. 
Source: http://www.newsgram.com/father-of-surgery-was-sushruta-the-first-plastic-surgeon-in-600-bc/ 
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Aretaios from Cappadocia (5), (Figure 3) is known to be the first to describe 
and used the word “Diabetes” which is Greek, meaning "a siphon”, because 
people with diabetes "passed water like a siphon”.  
 
(Figure 3) Aretaios from Cappadocia. 
Source: https://en.wikipedia.org/wiki/Aretaeus_of_Cappadocia 
 
John Rollo (6), a Scottish surgeon, deceased 1809, was the first person using 
the term “diabetes mellitus”, where the word “mellitus” means “honey” or 
“sweet” which was described earlier by Thomas Willis year 1674 who tasted 
the urine and described its flavour by adding the term “mellitus”. He also 
described the first functional diet that could help those with the disease. He 
thought glucose was made in the stomach from vegetables and his “diabetic 
diet” also called the “animalistic diet” consisted mainly of fat and meat. 
With some modifications, this was actually the only treatment of the disease 
until beginning of the 1920s. A famous variant of this diet was created by a 
Swedish doctor, Karl Petrén (1868-1927) consisting mainly of cabbage and 
killer in different forms rinsed with wine (7). French chemist, Michel 
Chevreull (1786-1889) showed that the sugar in human urine was glucose 
(8). 
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Claude Bernard (1813-1878) has a profound role in the history of DM 
research, since he discovered and mapped the metabolism of glucose and 
that it could be find in the bloodstream, also during fasting and not only 
during meals as one has though before. He also found that the liver 
contained a starch-like substance that he called “glycogen” meaning “sugar-
binding”(9). Paul Langerhans (1847-1888) discovered that the pancreas was 
designed as accretions of cells looking like islets (10). Some years later, 
Gustav Laguesse (1861-1927) suggested that these islets could be involved 
in secretion of a substance that could lower the glucose levels in the 
bloodstream. He called them the “islets of Langerhans” and later this 
hypothetical substance was called insulin, coming from the Latin, meaning: 
island (11). Another Scottish doctor, George Harley (1829-1896) noticed 
that there are at least 2 different types of diabetes that needs totally different 
treatment (12). Etienne Lancreaux (1829-1910) set a difference between fat 
and thin diabetes: diabéte gras and diabéte maigre. Before the discovery of 
the insulin these terms had a dramatic role seeing that the latter often died 
within a few months. After the discovery of insulin the dying group could 
survive and the other group could often live with a dietary treatment (13). 
 
The terms DM types 1 and 2 are actually given from anthropometry. In the 
1940s an American anthropologist named Dupertius measured body 
constitution in diabetic individuals (14). As an anthropologist, he had vague 
knowledge about diabetes and though it is one uniform disease. To his 
surprise, he realized that people with DM had totally different body 
constitution, which he classified as IA and IB. These where later named 
group I and II, and the latest classification as “type 1” and “type 2” diabetes 
was made by Andrew Cudworth in the 1970s (15). 
 
Before 1923, the chance was small for individuals to survive long enough in 
order to develop diabetes complications. However, the most common 
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complications were known as early as the beginning of 1800s. Domenico 
Cotugo (1736-1822) wrote in 1770 the first description of proteinuria with 
DM (16), while Wilhelm Griesinger (1817-1868) described albuminuria for 
the first time (17). 
 
In 1855, Eduard von Jaeger (1818-1884), draw the first picture of 
retinopathy in the ocular fundus on a diabetic 22-year-old patient with the 
new discovered ophthalmoscope (18). Julius Hirshbergh (1843-1925) was 
the first claiming that retinopathy was typical in DM patients and he 
classified these retinal findings to 4 different forms: retinitis centralis 
punctuate, haemorrhagic form, retinal infarction, and haemorrhagic 
glaucoma (19).  Although these expansive complications of DM disease 
were most clear after the discovery of insulin by Banting and McLeod 
(Nobel Prize 1923). Less than 10 years after this significant discovery, an 
American specialized in DM, Elliot P. Joslin (10) stated that, due to the 
discovery of insulin, we now move from the insulin-coma ages to the 
diabetes-complication age (6). Even if modern and improved measurements 
with portable blood glucose meters, more specific drugs, better blood 
pressure measurements and treatments are available, among ocular fundus 
screenings and laser treatments, we face the biggest global challenge ever 
due to increased prevalence of DM2. 
 
3. Ethnicity 
It is very often said that DM, particularly DM2, is a disease from the western 
world and habits. It is usually associated with the American lifestyle and 
many European countries, where the fast-food culture and sedentary work 
have a significant role. However, this is not far away from the truth, and we 
can clearly see that the prevalence of the disease is rapidly increasing all 
over the world (Fig. 4). Regardless of this association, the IDF (International 
Diabetes Foundation) reveals the fact, showing most of the increase happen 
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in low or middle income countries, and the trend appears to continue in 
years ahead. Lifestyles changes along with urbanization, for having a more 
westernized lifestyle has often been discussed and has been a subject for 
research, with proven facts that the prevalence of diabetes, for the same 
ethnical group, living in different areas, has been higher due to its outcome. 
At the same time the environment of these ethnical groups have varied and 
have shown different consequences. However, the most significant factor 
seems to be genetic factors regarding prevalence, progression and 
occurrence of sequelae between ethnical groups. 
 
 
 
(Figure 4) Estimated number of people with diabetes worldwide and per region in 2015 and 2040 (20-79 
years). Source: IDF Diabetes Atlas, Seventh Edition, 2015 
 
4. Clinical types  
As mentioned earlier, there are different ethnological classifications of DM.  
There are older sayings asserting that some main differences in classification 
of DM types 1 and 2 is the propensity of producing acids, so called ketones. 
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In older days scientist thought the production of ketones only seemed to 
appear in type 1 diabetes (DM1), due to destroyed islet cells caused of an 
autoimmune process, but also non-autoimmune DM1 was described which 
seemed to debut as dramatically as the classical forms with the difference 
that this form arise secondary after a chemical destruction of beta cells after 
acute form of pancreatitis, non-alcohol induced (20). However several cases 
of ketoacidosis have been noticed also in DM2 patients (21). 
 
Type 1: This DM type is characterized of a progressive betel destructivity 
which sooner or later will cause insulin deficiency, which means that the 
person suffering from this type of the disease need external injections of 
insulin in order to survive. Usually this is caused by an autoimmune 
response where antibodies attack islet tissue in the pancreas. The 
autoimmunity itself can be divided in two groups where one is referred to 
the fast progressive form and the other one, which is most common is called 
the slow progressive form or LADA (Latent Autoimmune Diabetes in 
Adults). 
 
Type 2: The DM2 covers the majority of all diabetic types. Variation in 
pervasiveness is usually seen and the disease progress undetected for several 
years before a diagnosis is set and the individual has by then often 
developed symptoms with complications. There are usually several causes, 
however the diagnosis presumes no signs of autoimmunity with 
destructiveness of the pancreas, and the fact that the individual has no other 
known reasons for having diabetes.  
 
It is said that there is a reduction in the amount of beta cells in DM2, but 
most of them exists and are intact. A small increase of A-cells leads to 
higher levels of the hormone, glucagon. Due to prolonged duration of the 
disease, the appearance of amyloid inclusion is seen in the islets of 
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Langerhans. With this said, scientists conclude that the quality and 
mechanisms and capacity of secretion is more important than the amount of 
functional cells in DM2 (22). More recently it has been said that DM2 is 
actually a slow progressive form of DM1 (13). Those can be identified with 
attribution of so called GAD-antibodies. This “new” form is seen mostly in 
normal or slightly obese individuals, referred to a group called LADA (23). 
However, old terms such as latent or chemical diabetes is more seldom used 
nowadays and new subtypes of DM 1 and 2 have been described and most 
diabetics adopts having type 1 or mixed forms of types 1 and 2.  
 
With this said, we could affirm that the prevalence of classical DM2 has 
reduced, not assert the amount of cases has been reduced, but more likely, 
those we used to call DM2 is discover having type 1 or type 1-alike diabetes. 
Individuals with DM2 suffer usually from an insulin resistance and some 
grade of insulin deficiency.  Furthermore, no insulin injection is necessary, 
at least during the first year, and changing lifestyle, diet and per oral 
medication might reduce the risk of injections. Let’s bear in mind that this 
type has a strong hereditary component which means that the disease results 
in interaction with several different genes, environmental factors, obesity, 
higher age and physical inactivity.  
 
(Figure 5) Diabetes Risk Factors. 
Source: International diabetes federation.http://www.idf.org/worlddiabetesday/toolkit/gp/risk-factors 
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5. Prevalence and incidence of diabetes mellitus type 2 
There is no ideal screening system to evaluate incidence of DM2. Preferably 
one with a yearly examination, with yearly-added new diagnosis of the 
whole population in each specific country. A study made in Laxå, Sweden, 
with a follow-up over 33 years showing an age standardized yearly 
incidence of about 3 new cases per 1.000 inhabitants (Jansson, 2010, 
Mortality trends in subjects with and without diabetes during 33 years of 
follow-up) and a retro-perspective study from Uppsala, also in Sweden, 
showing 3,8 cases per 1.000 inhabitants (22, 24). Another study from 
Gothenburg was the yearly incidence 4,3 per 1.000 inhabitants between ages 
51-60 and 4,9 per 1.000 inhabitants between ages 61-67. The cumulative 
risk of developing DM2 between age 61-67 was close to 8% (24). This is not 
far away from fact that the WHO represents for the whole world presented 
in their “key facts” below: 
 
Key facts from the World Health Organization (WHO) 
 
• The number of people with diabetes has risen from 108 million in 1980 to 
422 million in 2014 (25). 
• The global prevalence of diabetes* among adults over 18 years of age has 
risen from 4.7% in 1980 to 8.5% in 2014 (25). 
• Diabetes prevalence has been rising more rapidly in middle- and low-
income countries (25). 
• Diabetes is a major cause of blindness, kidney failure, heart attacks, stroke 
and lower limb amputation (25). 
• In 2012, an estimated 1.5 million deaths were directly caused by diabetes 
and another 2.2 million deaths were attributable to high blood 
glucose**(25). 
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• Almost half of all deaths attributable to high blood glucose occur before 
the age of 70 years (25).  WHO projects that diabetes will be the 7th 
leading cause of death in 2030 (26). 
• Healthy diet, regular physical activity, maintaining a normal body weight 
and avoiding tobacco use are ways to prevent or delay the onset of DM2 
(25). 
• Diabetes can be treated and its consequences avoided or delayed with diet, 
physical activity, medication and regular screening and treatment for 
complications (25).  
 
* Defined as fasting blood glucose equal to or higher than mmol/L, or on 
medication for raised blood glucose, or with a history of diagnosis of 
diabetes. 
 
** High blood glucose is defined as a distribution of fasting plasma glucose 
in a population that is higher than the theoretical distribution that would 
minimize risks to health (derived from epidemiological studies). High blood 
glucose is a statistical concept, not a clinical or diagnostic category. 
 
In Sweden, there are also gender related differences in incident risks and the 
prevalence of DM2. Apparently the disease is more common in women but 
this gender difference disappears when the whole population in all ages is 
considered. In higher ages, it’s more common in women, which could be 
related to higher diabetes incidence and lower mortality in women (24). 
 
6. The metabolic syndrome 
Gerald Reaven was the first one introducing this syndrome in 1988, 
described as “syndrome X” (27). The metabolic syndrome is referred to a 
group of risk factors related to cardiovascular disease, which all are related 
to insulin resistance (28). Suffering from insulin resistance among obesity, 
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particularly abdominal obesity, along with dyslipidaemia, hypertension, 
DM2 or decreased glucose intolerance connote a significant higher risk of 
diseasing or even death in cardiovascular diseases.  
 
6.1. Definition 
Due to its complicity, there is no single definition of the metabolic 
syndrome. However, all different definitions share the same major 
components as you can see in the table 1. 
The differences in these definitions may cause different prevalence 
figures and the cardiovascular disorder risks may differ, due to which 
definition is used in different population studies.  
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WHO    (1999) EGIR        (1999) 
NCEP ATP III               
(2001 revised 
2005) 
AACE      
(2003) 
IDF               
(2005) 
AHA/NHLBI 
(2005) 
Insulin 
Resistance 
IGT, IFG, DM2 
or decreased 
insulin 
sensitivity & 2 
of the following 
characteristics 
Plasma insulin 
>75% & 2 of the 
following 
characteristics 
No definition: 
3 of the 
following 
characteristics 
IGT or IFG & 
any of the 
following 
characteristics 
No definition No definition:  
3 of the 
following 
characteristics 
Obesity Waist size:  
men ≥0,9 
women ≥0,85 
&/or BMI >30 
kg/m2 
Waist size:  
men ≥94 cm 
women ≥0,80 
cm 
Waist size: 
men ≥ 102 cm 
women ≥88 cm 
BMI ≥ 25 kg/m2 Increased wist 
size 
(population 
specific) & 2 
of the 
following 
characteristics 
Waist size:  
men ≥ 102 cm 
women ≥88 
cm 
Dyslipidemia 
(mmol/l) 
TG ≥1,7&/or 
HDL:  
men< 0,9 
women ≥1,0 
TG ≥1,7&/or 
HDL:  
men& women < 
1 
TG ≥1,7 
HDL:  
men ≤ 1,0 & 
women ≤ 1,3 
TG ≥1,7 
HDL:  
men< 1,0 & 
women< 1,3 
TG ≥ 1,7 or 
treatment 
against high 
TG 
HDL:  
men ≤ 1,0  
women ≤1,3 
or with 
treatment 
TG ≥ 1,7 or 
treatment 
against high 
TG 
HDL: 
men ≤ 1,0 
women ≤1,3 
or with 
treatment 
Hypertension 
(mmHg) 
≥ 140/90 ≥ 140/90 or 
hypertension 
treatment 
≥ 130/85 ≥ 130/85 SBP ≥ 140 or 
DBP ≥ 85 or 
with 
hypertension 
treatment 
SBP ≥ 140 or 
DBP ≥ 85 or 
with 
hypertension 
treatment 
Glucose 
(mmol/l) 
IGF, IFG or 
DM2 
IGT or IFG (not 
diabetes) 
> 6,1 IGT or IFG (not 
diabetes) 
≥ 5,6 ≥ 5,6 or 
diabetes 
treatment 
Other Micro-
albuminurea 
  Other insulin resisters 
characteristics (family history of 
DM2, polycystic ovarial 
syndrome, inactive life-style, age 
& some ethnical relation to a high 
risk group of DM2) 
 
 
(Table 1) Different definitions of the Metabolic Syndrome. Source: Carl-David Agardh and Cristian Berne. 
Diabetes. 4th rev. Stockholm: Författarna och Liber AB; 2009. Part 1, Definition, diagnostik och klassificiering: 
p.28 
 
Abbreviations: WHO (World Health Organisation), EGIR (European Group for the Study of Insulin Resistance), 
NCEP ATP III (National Cholesterol Education Program Adult Treatment Panel III), AACE (The American 
Association of Clinical Endocrinologists), IDF (International Diabetes Federation), AHA/NHLBI 
(American Heart Association and the National Heart, Lung, and Blood Institute), IGF (Insulin Like Growth 
Factor), IFG (Interferon gamma), DM2 (Type 2 Diabetes Mellitus), BMI (Body Mass Index), TG 
(Transglutamase), HDL (High Density Lipoprotein), SBP (Systolic Blood Pressure), DBP (Diastolic Blood 
Pressure), mmol/l (milimole per liter), mm Hg (millimeter Quicksilver)  
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6.2. Cause 
There is a multifactorial background to the metabolic syndrome where 
life-style, metabolism and genetic factors all play its role somehow. Age, 
ethnicity, gender and social-economic factors influence the prevalence. 
Figures about 15-40% have been reported for adults’ population in a 
westernized population. The prevalence increases with age in young 
adults and starts to decrease about their 70s.  
 
Unfortunately, the increase is major in the USA, Europe and Asia, due 
to its similarity in life-style changes and the occurrence of obesity, 
waist-obesity and DM2. It is said that about half of the factors causing 
the metabolic syndrome is due to heredity and the other half due to the 
life-style, which indicates higher energy intake, stress and less physical 
activity. In genetic studies with help of singe nucleotide polymorphism 
(29), in both DM2 and insulin resistance, indications that the “old” gene 
(ancestral gene) is associated with increased risk, while mutations 
occurring in later generations are protected from metabolic deviations. 
This leads to the fact that recent life-style and habitat is the dominating 
cause to this powerful increase of the metabolic syndrome, in many 
populations. There is also known that stress, anxiety, depression, lack of 
sleep, using tobacco and alcohol all contributes in development of the 
metabolic syndrome. In women with insulin resistance, with heightened 
level of testosterone levels among low levels of the sexual hormone 
binding globulins (SHBG), results in higher free testosterone levels, 
which is related to the metabolic syndrome. 
 
In this syndrome, the risk of cardio-vascular diseases is about doubled in 
all age categories. The risk is also increased if more factors behind it are 
presence. If one has DM2, the risk of having the metabolic syndrome is 
about four to 6 times higher compared with those not having DM2.  
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About 90% of people suffering from DM2, teenagers up to 70-80 year old 
individuals, all fulfil the criteria for metabolic syndrome. It should be 
mentioned that the metabolic syndrome is not very rare in DM1, since about 
22% of the patients in the Diabetes Control and Complication Trial (DCCT), 
fulfilled the criteria, following IDFs criteria, at start of the study. It has been 
shown that individuals with DM1 fulfilling the criteria for the metabolic 
syndrome have higher risk developing cardiovascular diseases and 
microvascular complications.  
 
7. Other diabetic types 
 
7.1.  Genetic defects in beta-cell-functionality 
 
7.1.1. MODY (maturity-onset diabetes of the young) is a variant 
where mutation in genes causes the disease. Less than 5% of this 
type causes DM2. So far, this type of mutations has been found in 
several genes with different symptoms. Therefore giving name to 
MODY 1, MODY 2 up to MODY 6. 
 
7.1.2. Mitochondrial diabetes, also called MIDD (30). As the 
name indicates this type is inherited from the mother and associated 
with deafness. There are so far 40 types of mitochondrial mutations 
and these mutations stands for about 1% of all cases of diabetes (30). 
 
7.1.3.   Genetic defects that influences the effect of insulin 
These types are very rare types, except in lipoatrofic diabetes, which 
is caused by a mutation in an insulin-receptor gene, called A-insulin 
resistance. This mutation causes many different types of symptoms 
and syndromes, such as Donahue-syndrome and Rabson Mendenhall 
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in children. Lipoatrophy, hyperinsulinemia, DM, 
hypertriglyceridemia, acanthosis nigricans and liver steatosis might 
be other difficulties these mutations might cause. 
 
Also worth mentioning in this category one might suffer from:  
 
• Diseases in the exocrine pancreas 
• Endocrine diseases 
• Medical or chemical induces diabetes 
• Inflectional diseases 
• Specific forms of immune-mediated diabetes 
• Other genetic syndromes associated with diabetes  
• Pregnancy diabetes  
 
 
7.2.  Diabetes mellitus diagnosis 
The debut of DM classical symptoms is sometimes very sudden, with: 
frequent and lots of urination, thirst, unplanned weight-loss, infections 
and poor vision. In worst-case scenarios, ketoacidosis might happen and 
if not rapidly treated, lead to ones death. Usually the symptoms are less 
complicated and severe, with hyperglycaemia during long periods, 
before the prognosis is obvious. However, when a diagnosis is 
determined the individual might have developed complications. 
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7.2.1.  Diagnostic criteria 
In order to determine the diagnosis of DM, it needs to be evidence 
of high plasma glucose levels in the bloodstream. Generally, DM 
represents a group of metabolic diseases, which are characterised by 
hyperglycaemia, which is usually a cause of shortage in insulin 
secretion or insulin defects, or both together. Temporary or 
occasional rise of the plasma glucose that might have been caused 
due to extreme stress, difficult infections or trauma is therefore not a 
criteria for putting the diagnosis. Through the years, the criteria have 
differed and the first general criteria were introduced by the 
National Diabetes Data Group in the USA and by the World Health 
Organization (WHO) in 1980. After nearly two decades, in 1999, 
further changed was introduced by the (WHO) and used by medical 
professionals until more recent years. Most recent changes have 
been presented by the American Diabetes Association. 
 
(Table 2) Venous plasma glucose 2 hours after ingestion of 75 grams oral glucose. (2)  
Source: Författarna och Liber AB; 2009. Part 1, Definition, diagnostik och klassificiering: p.28 
Abbreviations: WHO (World Health Organization), ADA (American Diabetes Association), IGT 
(Impaired Glucose Intolerance), IFG (Impaired Fasting Glucose) 
 
 
 
 
25 
 
 
7.3.  Managing diabetes mellitus prevention and therapy 
In all DM types, the aim of treatment is always to achieve normal 
plasma glucose levels in hope to reduce the risk of hypoglycaemia. The 
main pillars of the treatment are an adapted diet and physical activity for 
the individual with the self-care as a key point. Except diet control and 
physical activity, there are several other methods of prevention and 
treatment of DM. Among these, oral medications such as metformin, 
which is among the bi-guanides that helps, decrease the production of 
glucose in the liver. They also decrease how much glucose the intestines 
absorb and makes the body more sensitive to insulin, and help muscles 
absorb glucose. 
 
Glitazones, which are among the sulfonylureas, which are among the 
oldest diabetes drugs, still used today work by stimulating the pancreas 
with the help of beta cells. This causes the pancreas to make more 
insulin.  
 
Other medications such as meglitinides help release insulin from the 
pancreas. Thiazolidinediones work by decreasing glucose in the liver. 
They also help fat cells use insulin better.  
 
Glucagon-like peptides are similar to the natural hormone called 
incretin. They increase B-cell growth and how much insulin the body 
uses. They decrease appetite and how much glucagon the body uses. 
They also slow stomach-emptying which all are important actions for 
patients with DM. 
 
If diet control, physical activity and oral medications are not given 
satisfactory results in the DM patient, combined with insulin medication 
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which most frequently used as injections in fat tissues can be used. There are 
short-acting, rapid-acting, intermediate-acting, long-acting and combination 
insulin that either individually or in combination are used to obtain 
maximum balance of blood glucose to reduce the risk of hypo or hyper 
glycaemia. 
 
7.3.1.   The importance of prevention of diabetes mellitus type 2 
Some suggestions have been made on big groups of people in the 
USA during a long period of life, regarding the effect of regular 
physical activity and development of DM2. A follow-up of 87.000 
women and 21.000 men in their middle ages, during 8 years showed 
that those individuals with at least 30 minutes of physical activity at 
least once a week, reduced their risks getting affected over 30%. 
There are of course many arguments why DM2 should be prevented. 
It is often said that the disease increases epidemically and that costs 
and maintenance of the disease is a big effort for every countries 
health care system. However, studies have shown that changing life-
styles in individuals with high risk of developing the disease and/or 
with some oral medicament treatments might have preventive 
outcomes (31, 32). Also, obesity and bariatric surgery, more known 
as gastric banding or gastric bypass and gastric-plastic surgeries, 
have led to decrease in medication for DM2 patients or even ending 
treatment due to loose of with and changing lifestyle. A study made 
on 22.000 individuals with high body mass index, undergone some 
type of surgery due to obesity, showed results of 75% of the 
participants could terminate usage of oral medication. Since today’s 
ability of affecting the beta-cells in pancreas is limited, we are 
suggested to focus on the insulin effect. This goal is most effectively 
achieved if focus is on change of lifestyles, possibly with types of 
pharmaceuticals designed to prevent insulin resistance, mainly in 
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people with higher risk factors developing the disease, such as: 
obesity, physical inactivity, use of tobacco and stress. 
 
8. The diet 
Understanding the importance of balanced diet and the ability to control, 
prevent and treat individuals with dietary treatments is fundamental in 
prevention of insulin intolerance, especially for people with DM2. The aim 
of dietary treatments or dietary awareness is to prevent vigorously 
symptomatic plasma glucose turns, which could cause complications.  
 
In this effort, the target is not only the plasma glucose control, but also 
reducing the risk of hypertension and development of disorders in the lipid 
metabolism among coagulation disorders and fibrinolysis. These mentioned 
risks are all linked to possible development of insulin-resistance and all 
these risk factors are included in the so-called “metabolic syndrome” that we 
will be more closely described further below.  
 
Studies has provided evidence supporting a beneficial effect from the 
traditional Mediterranean diet on the risk of DM2 and metabolic syndrome. 
A recent meta-analysis of prospective cohort studies showed that greater 
adherence to the Mediterranean diet was associated with a significant 
reduction in the risk of diabetes.  
 
The Mediterranean diet has also been found to be beneficial in the 
prevention of gestational diabetes. Results have show that participants 
assigned to the Mediterranean diet had a significant 30% reduction in the 
risk of DM2 and that it also promoted the reversion of metabolic syndrome 
and its components, hyperglycaemia and central obesity (33). 
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9. Physical activity 
In DM1 patients, without any complications, physical exercise shows 
improving effects in the cardiovascular functionality, it might even reduce 
any hyperlipidaemia and increase the general health quality. However, it 
does not control of glucose improve with physical exercise.  
 
It is recommended and sometimes vital, for a person with DM1, to decrease 
the amount of insulin or intake of extra carbohydrates, or often both, prior to 
any extreme physical activity. In DM2, which are the most common type, is 
usually followed by obesity, hypertension, dyslipidaemia, and severe insulin 
deficiency.  
 
All of these factors, individually might be a profound cause of 
cardiovascular complications. This leads to the fact that necessary treatment 
for this type is to normalize glucose and lipid levels in the bloodstream as 
much as possible.  
 
Traditionally a combination of changing lifestyle and diet habits with oral 
medications are used to attain set treatment goals. Lower energy intake and 
higher energy consumption is the simple rule for this treatment. If/when this 
treatment is insufficient in order to obtain normal glucose balance, guidance 
from the USA (34) and Europe (EASD) stated 2009, suggests 
pharmacological treatment which will be more closely explained below. 
 
10. Oral medication  
As mentioned earlier, if or when physical activity and proper diet treatment 
are not sufficient in order to obtain normal glucose balance, it is suggested to 
use pharmacological treatments with metformin, which is a bi-guanid with 
antihyperglycaemic effects which both decreases the basal and post gradual 
levels of plasma blood glucose (35). Notwithstanding stimulation of insulin 
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secretion and therefore not cause hypoglycaemia. It has been suggested that 
treatment with metformin should begin as soon as the diagnosis of DM2 is 
determined (36) which some healthcare professionals plainly do not agree 
upon.  
 
11. Use of insulin 
Before 1922, everyone suffering of DM1 deceased shortly after onset of the 
disease. The discovery of insulin has been of such importance in our world 
and has been priced with the Nobel Price the year after its discovery. First 
person treated was Leonard Thompson, a 13 year old boy from Toronto, 
Canada (37).   
 
The drug has developed significantly during the years and today we use such 
perfect combinations of amino-acid sequences and high degree of 
purification, which makes the insulin identical to human insulin. We are also 
able to modificate its properties for selective uses and these types are called 
insulin analogues.  
 
The injection supply has reached such perfection that insulin pens can be 
used and many other different researches and inventions are being tested to 
create even better injection methods, among these also insulin pumps are 
other inoperable options, which gives more precise and customized 
treatment with better glucose control in relation to meal related requisites. In 
spite of improvements and the technology, usage of insulin demands great 
knowledge from the user.  
 
Many often users will experience hypo- or hyperglycaemia episodes due to 
miscalculations or not fair predictions of ones digestion and physiology. 
Great patient-healthcare contact is required in order to tailor decorous usage 
of the drug. Many times, it’s advised to the patients, to connect with other 
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individuals suffering from the same disease, in order to apprehend and 
utilize the drug fairly in their daily life.  
 
12. Transplantation 
Despite great technology and methods of treatment with insulin, whether 
with insulin pens or pumps, in DM1 patients, sometimes the desired 
treatment isn’t fulfilled. Which leads to daily life complications effecting the 
individuals’ private life, family life, education possibilities and work life. 
It’s worth mentioning that even today, sudden death in young individuals, 
treated for DM1, is surprisingly high. It is thought that about 6% of all 
deaths in people below 40 years old, suffering from DM1, high be caused 
from a hypoglycaemia leading to a ketoacidosis, more commonly described 
as “dead in bed syndrome” (38). Patients with this type of unstable disease 
with frequent hypoglycaemia tend to under-treat themselves resulting 
worsening blood glucose controls and higher risk for complications. 
Scientists agree upon the fact that antipathy in DM1 is caused by the 
metabolic disorders which itself is a result of malfunctioning of the beta-
cells in the islets of Langerhans. This fact has led scientist to believe of a 
cure for the disease through transmitting of functional beta cells. There are 
two different ways of transplanting functional cells to such patients. One of 
them is by transplanting a whole new pancreas (39). Although this sounds 
promising, there are too great dangers for someone planned undergoing 
transplantation. Specially if the individual haven't already or is not about to 
remove or transplant a kidney, both because of the operation itself and 
because of the immunosuppressive treatment that follows. Therefore, only a 
pancreas transplant solely is seldom advised and must be predicted to result 
to great advantages before it’s performed. 
 
The other method used is to just take isolated islets of Langerhans so called 
“islet transplantation” (40). The latter has been more enticing since only the 
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islets needed is transplanted. The result of transplantation has been very 
promising and developed rapidly since it first was first performed in the 
USA, Minneapolis, year 1966. 
 
13. Self-care 
The concept of “self-care” was originally introduced for easier disease 
conditions, which could be managed self-handed. Great responsibility and 
knowledge about the disease, condition that might betide and treatments is 
requested from the patient, in order to minimize risks and complications. 
There are times when a patient, suffering from diabetes should be more 
observant. For example, before trips abroad or if getting acute diseases and 
infections. They should always think about suitable diet, physical activity. 
Always be careful in use of tobacco, use of alcohol and in traffic. They 
should pay attention to signs of neuropathy, signs of undesirable sudden or 
prolonged aces in the musculoskeletal system. There should be awareness 
for cardiovascular signs, pregnancy and menstruations disorders and 
preferably also care extra about oral health and sleeping habits or disorders. 
Modern methods of treatment for DM patients are based on good 
collaboration between the patient and the health-care team involved (41). 
This chronic and sometimes life threatening disease calls for a considerable 
contribution of the patient with enough knowledge about the disease and its 
complications. One of the hardest tasks for the health-care providers are to 
educate these individuals about the assignations that need to be carried out 
by the patients alone and often single-handed. Mainly, the actions and 
precautions required of the patient is to understand the mechanisms of their 
disease, how to measure their blood glucose levels, learn how to use the 
treatment suggested, either if it is tablets or with insulin. Furthermore, the 
patient needs to decide when contact with the healthcare should be made in 
order to avoid complications. However, the healthcare providers need to 
have trained doctors and nurses, ready to guide the patient whenever needed 
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with regular instructions and education about the disease and if new 
guidance and better suitable drugs are introduces in the market. Regular foot 
care or chiropody is always recommended (43, 44). Individual physical 
exercise programs and other screenings aimed for specific complications are 
essential which will be more closely discussed in next chapter. 
 
14. Complications 
During prolonged diagnosis with diabetes, one usually finds complications 
from smaller and bigger blood vessels in the human body. The problem is 
seen in many parts of the body and organs, such as the vessels in the eye, 
kidneys and the nervous system. Also, a higher risk for developing 
atherosclerosis in coronary vessels and those vessels in the brain. Not to 
forget risks for diabetic foot ulcers.  
 
I will briefly mention these complications as follows; 
 
14.1.   Microangiopathy 
This term is a collective term referring to the biochemical, structural and 
haemodynamic changes occurring, in smaller vessels, in different organs 
due to conical hyperglycaemia such in diabetes. Body parts usually 
affected by microangiopathy are in the retina in the eye (retinopathy), 
the glomeruli in the kidneys (nephropathy) and the vasa nervorum in the 
nervous system (neuropathy) (42). The most usual complication is 
retinopathy in the eyes and the most usual cause of blindness below age 
65 in the western world (43). Nephropathy is one of the most usual 
causes to uraemia, which means higher level of urine in the bloodstream, 
indicating kidney failure. Peripheral neuropathy is a strong contributor 
to diabetic foot ulcers risking amputations in extremities.  
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14.2.   Macroangiopathy 
The changes occurring in bigger or middle-sized vessels are quite 
identical in their evolution such as atherosclerosis. Although the 
outcome and development of plaques are similar, the process is much 
higher and usually more aggressive in diabetic patients, which leads to 
more complications (5). The cause of this rapidness and aggressively is 
not yet discovered but, so far, it’s been shown that there is a high 
oxidative stress in the endothelium cells which seems to have a profound 
role in the process. Also, increased glycation and lipid oxidation might 
be involved in the damage and inflammations caused in the vessel walls 
and mechanisms directly connected to the development of plaques (44). 
Let’s have in mind that presence of hypertension, hyperlipidaemia and 
low HDL-cholesterol among coagulation disturbances are important 
factors to cardiovascular diseases in diabetes patients. Microangiopathy, 
which has been discussed earlier might bind links to the increased 
complications in diabetic patients, suffering from cardiovascular 
diseases.  
 
14.3. Hypertension  
High blood pressure is an important risk factor in development of macro 
and microangiopathies (45). There is strong scientific support, showing 
that development of nephropathy is decreased when treatment of 
hypertension is initiated in DM1 patients (46). Hypertension is usually 
followed by nephropathy in these patients. There are several causes, 
developing hypertension in DM2, notwithstanding that hypertension 
most likely precede DM2 diagnosis than being a cause of it. Most of the 
causes are linked to chosen lifestyle habits and It seems to be very 
important to start treating for hypertension early in the disease, if 
indicated, since evidence has shown that cardiovascular diseases and its 
complications are decreased and lower mortality is observed, 
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specifically in the development of stroke. Even though reduced risk in 
nephropathy and retinopathy is also benefits gaining from hypertension 
treatment in these groups of patients. 
 
14.4.   The diabetic foot 
This term is used as a collection of complications such as: ulcers, 
infections, destruction of deeper tissue associated with neuropathy and 
periphery vascular diseases in lower extremities. In the western world, 
the diabetic foot is the main cause of hospitalization (47) of these groups 
of patients. The treatment is very costly, especially in situations when 
amputation is necessary, where length of stay, rehabilitation and 
increased need of home nursing is required. It is calculated that of all 
amputation, about 40-50% (excluding trauma or malignity) is due to 
diabetes. In some countries up to 70-90%. Population based studies 
regarding amputation in lower extremities are limited. The incident (48) 
is considered to be about 7 and 206 per 100.000 inhabitants per year. 
The highest reported incidents are from American-Indian sanctuaries 
and the lowest reported are from Denmark. The differences are due to 
demographical factors, diagnostic and treatment of diabetes among 
different reporting systems. Most of the amputations are made below the 
ankle and 80% of them were previously caused by an ulcer. The most 
usual cause of amputation is gangrenes and infections. Slow healing or 
even not healing ulcers is not an indication for amputation. These foot 
complications in diabetes patients represent a serious threat, both 
towards the patients’ extremities and for their survival.   
 
14.5.   The diabetic eye 
According to the National Eye Institute (NEI, USA), diabetic eye 
disease includes a variety of ocular pathologies that affect to the diabetic 
patients. Mainly the DR, the diabetic macular edema (DME), cataracts 
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and glaucoma. All of these DM-related disorders potentially cause 
visual impairment and blindness. In fact, DR is the main responsible of 
vision loss and blindness among working age adults worldwide. Early 
detection and accurate therapy and follow-up of the affected patients are 
major protecting strategies for fighting against diabetic blindness. 
 
The DR is a microvasculopathy affecting the retina as well as the 
vitreous body that can be classified according to the Early Treatment 
Diabetic Retinopathy Study (ETDRS) criteria (X). Main ocular fundus 
signs and symptoms of DR are: microaneurisms, haemorrhages, hard 
exudates (spots corresponding to lipidic storage), soft exudates (spots 
corresponding to accumulation of axoplasmic detritus inside the axons 
of the ganglion cells), dilation and tortuosity of the veins, and 
intraretinal microvascular abnormalities (IRMA).  
 
Figure 6 shows the ocular fundus appearance according to the DR stages 
(ETDRS classification). According to the epidemiological studies, the 
risk of initiation and progression of DR is closely related to the type and 
duration of diabetes, blood glucose, blood pressure and lipidic profile. It 
has also to be considered that long term lesions of DR are characterized 
by a complex array of vascular and neurodegenerative changes leading 
to the apparition of specific areas of retinal ischemia.  
 
This, in turns, frequently triggers the onset of macular edema and/or the 
proliferative stages of DR with risk of visual impairment and blindness. 
Inflammation and neurodegeneration has also been reported in the 
diabetic retina in human and experimental diabetic models of 
retinopathy. 
 
 
 
36 
 
 
(Figure 6) Retinopathy Stages. A: Initial DR, B: Mild DR, C: Moderate DR, D: Severe DR, E: 
Very severe DR, F: Proliferative DR. Source: Extracted from doctoral thesis of Dr. MARÍA JOSÉ 
ROIG REVERT (49) 
Different cellular pathways and a variety of molecular mechanisms 
have been implicated in the DR, such as the increased polyol 
pathway flux, augmented advanced glycation end-products (AGE) 
formation, alterations in the activation of signalling cascades 
(among them the protein kinase C, (PKC)). Pathway, elevated 
oxidative stress, increased hexosamine pathway flux, and others. 
Interestingly, the above signalling pathways are in relation to 
oxidative stress, inflammation, and ischemia, therefore inducing up-
regulation of a wide spectrum of factors such as insulin-like growth 
factor (IGF), stromal derived factor-1 (SDF-1), vascular endothelial 
growth factor (VEGF), angiopoietins (Ang-2), tumour necrosis 
factor (TNF), and basic fibroblast growth factor-2 (bFGF) 
contributing themselves to the pathogenesis of DR, as can be seen in 
the figure 7. 
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(Figure 7) Major mechanisms involved in diabetes retinopathy (DR) (elevated polyol pathway flux, 
augmentation of AGE formation, activation of PKC and increased polyol pathways). 
 
After an intensive search of the scientific literature, it became 
evident that the mechanisms involved in the pathogenesis of DR, 
reflects a single hyperglycaemia-induced process. However, it is 
presumable that the above-mentioned pathogenic mechanisms 
involved in DR are interactive and interdependent. As a 
consequence of this, the contributions of large trials and preclinical 
research into the underlying mechanisms of action of the processes 
involving the onset and progression of DR could lead to new 
treatments of the disease to avoid the diabetic visual impairment and 
blindness. 
However, further research is needed to achieve full knowledge of 
the risk factors and pathogenic mechanisms occurring in the diabetic 
retina to achieve better eye care in diabetics. 
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15. Mortality in diabetes mellitus type 2 
Mortality in age standardizing DM2 patients is approximately twice as high 
than for those without the diagnosis (50). For individuals in their middle 
ages, the expected reduction of living years is about 5-10 years (24). 
However, several population studies from Denmark, Holland and Sweden 
has shown that mortality in DM2 has decreased around 4% yearly over the 
past decade (24). Cardiovascular diseases, in particular myocardial 
infarctions and stroke have been the main cause of death in DM2 patients. 
Occurrence of these causes has been reported to be twice to four times 
higher in DM2 patients compared with those not suffering from the disease. 
Risk factors to increased risk of mortality in DM2 is age, male gender, 
prolonged disease duration with poor glucose control among cardiovascular 
factors such as usage of tobacco, hypertension, lipid disorders, abdominal 
obesity and indigent physical activity. During 2006, 47.039 Swedish women 
and 44.232 Swedish men, which is equivalent to 1.028 per 100.000 women 
and 982 per 100.000 men from the means population, died (48). The amount 
of population dying from diabetes as the main cause was 972 women and 
1.025 men whence 941 women and 984 men were diagnosed with DM2 or 
non-specific type of diabetes. This gives a mortality rate of 16,8 for women 
and 26,9 for men in each 100.000 of the mean population. These figures 
have been pretty much alike for women since the 1980s while it has been 
increasing slightly for men since 1998. The mortality rate increases with age, 
which gives us the fact, that 6,7 of each 100.000 women in ages between 45-
64 years old, 27 in ages between 65-74 and 160 in ages above 74. For men, 
the similar mortality rate showed 12 of each 100.000 in ages between 45-64, 
54 in ages between 65-74 respectively 213 for those above 74 (2). 
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16. Molecules involved in diabetes risk and progression 
There are several studies searching for biomarkers of DM risk and DM 
complications. Among the outstanding molecules: vitamins, minerals, 
homocysteine (Hcys) and oxidative stress metabolic by products, have 
extensively been reviewed in relation to DM and the diabetic course (51-53).  
In upcoming paragraphs we will study different vitamins of importance to 
the project carried out.  
 
16.1.   Vitamins 
There are well-documented complications caused by DM2, which is 
affecting a remarkable proportion of the world’s population. DM2 is 
considered to be one of world’s most chronic diseases (54). 
 
16.1.1. Vitamin B12 
This vitamin, also known as cobalamin, is a water-soluble vitamin 
with a key role in the normal functioning of the brain and nervous 
system, and for the formation of blood. It is one of the eight B 
vitamins. It is normally involved in the metabolism of every cell of 
the human body, especially affecting DNA synthesis and regulation, 
but also fatty acid metabolism and amino acid metabolism (55). The 
effective use of vitamin B supplements, in general, has been 
described for prevention of cardiovascular disease in individuals 
with kidney disorders (56). Vitamin B12 is known to be essential in 
maintaining the general integrity of the vascular system, among 
others B vitamins.  It is known that individuals using the drug 
metformin, may reduce their serum FA and vitamin B12 levels 
which substantially increases the risk of B12 deficiency, which in 
turn might be an independent risk factor for cardiovascular disease, 
especially among individuals with DM2 (57). 
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16.1.2. Vitamin B9 (Folate, folic acid) 
Folate, also known as folic acid, vitamin B9 and vitamin M (58), is 
as important as vitamin B12 in the maintenance of the overall 
integrity of the vascular system. The human body needs folate to 
synthesize DNA, repair DNA, and methylate DNA as well as to act 
as a cofactor in certain biological reactions (59) We all require folate 
to produce healthy red blood cells and prevent anaemia (60). Folate, 
together with B12, contributes requisite absorption of essential 
nutrients. It has also been shown that individuals suffering from 
diabetic peripheral neuropathy have had significant improvements 
from their symptoms (61). 
 
16.2.   Homocysteine 
Hcys is a non-protein amino acid. It is a homologue of the amino acid 
cysteine, differing by an additional methylene bridge. It is 
biosynthesized from methionine by the removal of its terminal Cε 
methyl group.  Hcys can be recycled into methionine or converted into 
cysteine with the aid of certain B-vitamins. A high level of Hcys in the 
blood (hyperhomocysteinemia) makes a person more prone to 
endothelial cell injury, which leads to inflammation in the blood vessels, 
which in turn may lead to atherogenesis, which can result in ischemic 
injury (62). Hyperhomocysteinemia is strongly associated with 
increased risk of cardiovascular disease (53). Coronary artery disease 
occurs when an atherosclerotic plaque blocks blood flow to the coronary 
arteries, which supply the heart with oxygenated blood. Hcys has been 
associated to cardiovascular diseases and atherovascular plaques in the 
arteries such as the complications mentioned earlier in DM2 patients 
affected by macroangiopathies. 
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16.3. Oxidative stress biomarkers 
In a cell, different stress factors might cause a chemical reaction 
involving the loss of electrons or an increase in the oxidation state. This 
is more commonly known as oxidation. Although oxidation reactions 
are crucial for life, they can also be damaging if it exceeds from the 
physiological levels. The oxidation reactions can produce free radicals, 
which in turn could start a chain reaction that could be hazardous to the 
cell and could cause damage/death to the cell.  
 
 
(Figure 8) Oxidation process (Extracted from Pinazo-Durán et al., Clin Inter Aging 2014) (63) 
 
Furthermore, the chain reaction of lipid peroxidation was initiated by 
the superoxide anion (O2.-) that in the presence of hydrogen peroxide 
triggers the formation of hydroxyl radical (OH.) the most damaging to 
cells and tissues. The following reactions were set up by Haber-Weiss 
and Fenton to explain the generation of free radicals in the presence of 
oxygen, hydrogen peroxide and iron. 
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Antioxidant defences stop terminate these chain reactions by removing 
free radical intermediates, and inhibit other oxidation reactions. They 
do this by being oxidized themselves. An insufficient level of 
antioxidants, or inhibition of the antioxidant enzyme, causes oxidative 
stress. Oxidative stress is the result of the imbalance between the pro-
oxidants and antioxidants leading to damage to cell structure and cell 
function by overly reactive oxygen species (ROS) and chronic 
excessive inflammation. Oxidative stress seems to play a significant 
role in many human diseases, such as diabetes (64, 65). In many of 
these cases, it is unclear if oxidants trigger the disease, or if they are 
produced as a secondary consequence of the disease and from general 
tissue damage (66). Antioxidants are molecules that inhibit the 
oxidation of other molecules. There is increased evidence that these 
complications induce metabolic derangements leading to oxidative 
complications and stress. Vast investigation has been done the past 
decades in this field, in the development of diabetes complications (67, 
68). Stimulation and imbalance between production and elimination of 
ROS and reactive nitrogen species (RNS) (66) is a common cause of 
diabetic hyperglycaemia. Oxidative stress is associated with increased 
production of ROS or with a significant decrease in the effectiveness of 
antioxidant defences (69). As mentioned before, complications from 
micro- and macroangiopathies, such as DR, nephropathy, neuropathy, 
atherosclerosis and cardiovascular disease, all have a significant role in 
the oxidative and nitrosative stress processes. Hyperglycaemia can 
stimulate an imbalance between production and elimination of reactive 
oxygen species (ROS) and reactive nitrogen species (66, 70, 71). 
 
Up today there is general agreement that ROS are involved in the 
physical, biochemical, molecular, and pathological changes associated 
with aging. Oxidative damage to lipids, proteins, and nucleic acids 
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accumulates and increases with age, whereas the antioxidant 
mechanisms decrease in parallel. These facts are closely related to age-
related diseases as glaucoma, age macular degeneration or DR.  
 
17. Genes involved in diabetes risk and progression 
 
17.1.  Genetic analysis and expressions 
Genetic analysis is the overall process of studying and researching in 
fields of science that involve genetics and molecular biology. There are 
a number of applications that are developed from this research and these 
are also considered parts of the process. The base system of analysis 
revolves around general genetics. Basic studies include identification of 
genes and inherited disorders. This research has been conducted for 
centuries on both a large-scale physical observation basis and on a more 
microscopic scale. Genetic analysis can be used generally to describe 
methods both used in and resulting from the sciences of genetics and 
molecular biology, or to applications resulting from this research. 
Genetic analysis may be done to identify inherited disorders, to make a 
differential diagnosis in certain somatic diseases, and to identify subjects 
in high risk for developing diseases. Genetic expression is the process 
by which genes are transcribed to messengers RNAs (mRNAs). Changes 
in the nucleotide sequence of the genome could lead to mutations, which 
result from errors during DNA replication or other types of DNA 
damage. When the genetic alteration affects to only one nucleotide, this 
definition could be also used for single nucleotide polymorphism (SNP) 
(29). The difference between mutation and polymorphism is based on 
allelic frequencies. It is a polymorphism when the allelic frequency for 
the minor allele is more than 1%. A polymorphism is a population 
attribute. Genetic polymorphism promotes diversity within a population. 
A gene is said to be polymorphic if more than one allele occupies that 
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gene’s locus within a population (13). Polymorphisms of DNA repair 
genes might be linked to distinct mutation rate, which is a genomic trait. 
Mutation can be neutral, deleterious, or beneficial, in terms of the fitness 
of the corresponding phenotype, yet such a classification is only 
meaningful in an evolving population, i.e., invoking the concept of 
polymorphism, which itself does not have any functional implications. 
The genomic distribution of SNPs is not homogenous; SNPs occur in 
non-coding regions more frequently than in coding regions or, in general, 
where natural selection is acting and “fixing” the allele (eliminating 
other variants) of the SNP that constitutes the most favourable genetic 
adaptation (72). Other factors, like genetic recombination and mutation 
rate, can also determine SNP density (73). Within a population, SNPs 
can be assigned a minor allele frequency. This is simply the lesser of the 
two-allele frequencies for SNPs. There are variations between human 
populations, so a SNP allele that is common in one geographical or 
ethnic group may be much rare in another. These genetic variations 
between individuals (particularly in non-coding parts of the genome) are 
sometimes exploited in DNA fingerprinting, which is used in forensic 
science. Also, these genetic variations underlie differences in our 
susceptibility to disease. The severity of illness and the way our body 
responds to treatments are also manifestations of genetic variations. 
There are several rare types of diabetes caused by a mutation in one 
gene. In this sense, Garin et al. reported that recessive mutations in the 
human insulin gene (74) result in permanent neonatal diabetes (74). 
However, diabetes is a complex disease with many genes related to the 
risk of its onset and progression.  
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17.2.  Genes 
Some candidate genes have been linked to DM and DR. A selection of 
the most relevant genes is enclosed below: 
 
17.2.1. TP53 
Tumour proteins p53, also known as transformation-related protein 
53 (TRP53), are encoded by homologous genes in various 
organisms such as TP53. This homolog is crucial in multicellular 
organisms, where it prevents cancer formation, thus, functions as a 
tumour suppressor (75). As such, p53 has been described as "the 
guardian of the genome" because of its role in conserving stability 
by preventing genome mutation (76). Hence TP53 is classified as a 
tumour suppressor gene (76-81). The name p53 was given in 1979 
describing a protein mass of 53 kDa. However recent techniques and 
sequencing of the human genome enabled to establish that the 
human TP53 gene encodes not only one, but at least 12 proteins, 
which are ranging from 28 to 53 kDa. All these p53 proteins are 
called the p53 isoforms (76). The International Cancer Genome 
Consortium has established that the TP53 gene is the most 
frequently mutated gene (>50%) in human cancer, indicating that 
the TP53 gene plays a crucial role in preventing cancer formation 
(76). TP53 gene encodes proteins that bind to DNA and regulate 
gene expression to prevent mutations of the genome (82).  
 
17.2.1.1. TP53 in diabetes mellitus type 2 
In the context of tumour suppression, p53 is an undisputedly 
critical protein. Functioning primarily as a transcription factor, 
p53 helps fend off the initiation and progression of tumours by 
inducing cell cycle arrest, senescence or programmed cell death 
(apoptosis) in cells at the earliest stages of precancerous 
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development. Compelling evidence, however, suggests that p53 
is involved in other aspects of human physiology, including 
metabolism. Indeed, recent studies suggest that p53 plays a 
significant role in the development of metabolic diseases, 
including diabetes, and further that p53’s role in metabolism 
may also be consequential to tumour suppression (83). Kung et 
al. (84), studied genetic variants in the TP53 gene of a 
humanized knock-in mouse model and showed that the R72P 
polymorphism of this gene had a significant impact on the 
metabolic response to a high-fat diet, demonstrating an 
association between TP53 polymorphisms and metabolism (84). 
This research group carried out another study using the same 
mouse model and found that R72 mice developed insulin 
resistance, islet hypertrophy, increased infiltration of immune 
cells, and fatty liver disease. Also, they observed more-severe 
obesity and glucose intolerance in R72 mice compared to P72 
mice, suggesting that this SNP predisposes to obesity and 
metabolic dysfunction (85). Scientists have found an association 
between Arg72Pro (R72P) polymorphism in the TP53 gene and 
DM1 (86) but the association between this gene and DM2 is still 
not clear. Gloria-Bottini et al. did not found any relation 
between TP53 gene and DM2 (87) whereas Gaulton et al. 
reported a significant association between the gene and this 
disease (29). 
 
17.2.2. TMCO1  
Transmembrane and coiled-coil domain-containing protein 1 is a 
protein that in humans is encoded by the TMCO1 gene. This locus 
encodes a transmembrane protein. Mutations at this locus have been 
associated with craniofacial dysmorphism, skeletal anomalies, and 
 
 
47 
 
mental retardation. Mutations at this locus have also been associated 
with open angle glaucoma blindness. Alternatively, spliced 
transcript variants have been described (88). 
 
17.2.2.1. TMCO1 in diabetes mellitus type 2 
This gene has been involved in ocular diseases. However, its 
role in DM and the diabetic eye needs further research in human 
and experimental animals. 
 
17.2.3. SLC23A2 
Solute carrier family 23 member 2 is a protein that in humans is 
encoded by the SLC23A2 gene (89, 90). The absorption of vitamin 
C into the body and its distribution to organs requires two sodium-
dependent vitamin C transporters. This gene encodes one of the two 
required transporters and the encoded protein accounts for tissue-
specific uptake of vitamin C. Previously, this gene had an official 
symbol of SLC23A1. The solute carrier (91) group of membrane 
transport proteins include over 300 members organized into 52 
families (91). Most members of the SLC group are located in the 
cell membrane. The SLC gene nomenclature system was originally 
proposed by the HUGO Gene Nomenclature Committee (HGNC) 
and is the basis for the official HGNC names of the genes that 
encode these transporters. A more general transmembrane 
transporter classification can be found in TCDB database. Solutes 
that are transported by the various SLC group members are 
extraordinarily diverse and include both charged and uncharged 
organic molecules as well as inorganic ions and the gas ammonia. 
As is typical of integral membrane proteins, SLCs contain a number 
of hydrophobic transmembrane alpha helices connected to each 
other by hydrophilic intra- and extra-cellular loops. Depending on 
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the SLC, these transporters are functional as either monomers or 
obligate homo- or hetero-oligomers.  
 
17.2.3.1. SLC23A2 function in diabetes mellitus type 2 
Analyses have shown that there were significant differences in 
the vitamin C consumption in energy intake, activity level, 
dietary fiber intake, nutritional supplementation status, drinking 
or not drinking, education level among the different vitamin C 
intake groups. There were also significant differences in age, 
sex, body mass index (BMI), smoking status and vitamin C 
intake between the DM2 group and the non-diabetes group, 
suggesting that there is a significant negative correlation 
between the dietary vitamin C intake and the risk of DM2 (92). 
 
17.2.4. MMACHC 
The exact function of the protein encoded by this gene is not known, 
however, its C-terminal region shows similarity to TonB, a bacterial 
protein involved in energy transduction for cobalamin (vitamin B12) 
uptake. It has been shown that this gene may be involved in in the 
binding and intracellular trafficking of cobalamin, and it is 
demonstrated that metformin treated diabetic patients have a higher 
prevalence of cobalamin deficiency (93). Hence, it is postulated that 
this protein may have a role in the binding and intracellular 
trafficking of cobalamin. Mutations in this gene are associated with 
methylmalonicaciduria and homocystinuria type cblC. 
Methylmalonicaciduria and homocystinuria type C protein also 
known as MMACHC is a protein that in humans is encoded by the 
MMACHC gene (94). The C-terminal region of the product of the 
MMACHC gene is similar to TonB, a bacterial protein involved in 
energy transduction for cobalamin uptake (94). 
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17.2.5. MMADHC 
Methylmalonicaciduria and homocystinuria type D protein, 
mitochondrial also known as MMADHC is a protein that in humans 
is encoded by the MMADHC gene (95). This gene encodes a 
mitochondrial protein that is involved in an early step of vitamin 
B12 metabolism. Vitamin B12 (cobalamin) is essential for normal 
development and survival in humans (96). Mutations in this gene 
cause methylmalonicaciduria and homocystinuria type cblD 
(MMADHC), a disorder of cobalamin metabolism that is 
characterized by decreased levels of the coenzymes 
adenosylcobalamin and methylcobalamin (95). 
 
17.2.5.1. MMADHC and MMACHC (vitamin B12) function 
in diabetes mellitus type 2 
Several cross sectional studies (97-99) and case reports (34, 100, 
101) have documented an increased frequency of vitamin B12 
deficiency among DM2 patients. 
 
17.2.6. MMP9  
Proteases of the matrix metalloproteinase (MMP) family are 
involved in the breakdown of extracellular matrix in normal 
physiological processes, such as embryonic development, 
reproduction, angiogenesis, bone development, wound healing, cell 
migration, learning and memory, as well as in pathological 
processes, such as arthritis, intracerebral haemorrhage (102) and 
metastasis (103). Most MMPs are secreted as inactive proproteins, 
which are activated when cleaved by extracellular proteinases. The 
enzyme encoded by this gene degrades type IV and V collagens and 
other extracellular matrix proteins (102). MMP9 is greatly up 
regulated during human respiratory epithelial healing (104). Using a 
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MMP9 deficient mouse model, it was seen that MMP9 coordinated 
epithelial wound repair and deficient mice were unable to remove 
the fibrinogen matrix during wound healing (105). When interacting 
with TGF-ß1, Gelatinase B also stimulates collagen contraction, 
aiding in wound closure (106). 
 
17.2.6.1. MMP9 function in diabetes mellitus type 2 
Coordinated extracellular matrix deposition is a prerequisite for 
proper wound healing, which is mainly orchestrated by MMPs. 
Diabetic wounds generally show compromised, wound healing 
cascade and abnormal MMP9 concentration is one of the cause. 
MMP9 gene promoter may result in altered expression of 
MMP9 in wounds of DM2 cases resulting into non-healing 
chronic ulcers in them (107). In addition, several studies show 
an association between MMP9 polymorphisms and diabetes. In 
example, Feng et al. found an interesting association between 
the MMP9 -1562C/T polymorphism and diabetic nephropathy in 
a Chinese population (108) being supported these results by 
other recent study carried out by Zhang et al. (109). 
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HYPOTHESIS AND OBJECTIVES 
 
 
1. Hypothesis 
DR is one of the most important causes of vision loss and quality of life 
related to vision worldwide. Early diagnosis is essential to promote visual 
prognosis. It consists not only in detecting loss of visual function, but also in 
defining the extent and depth of the lesion and its etiopathogenic 
characteristics, for a better diagnostic and therapeutic approach. However, 
practice indicates that subjective and objective ophthalmological 
manifestations appear on many occasions when the lesion is already at an 
advanced stage. The new advances in biomedicine and biotechnology and 
the development of computer science have favoured the emergence of new 
exploratory techniques, many of which have been a great help to the current 
ones, especially in relation to retinal diseases. Among these techniques, the 
analysis of the genetic expression, in relation to the oxidative stress and 
antioxidant defences stand out. In addition, the new disciplines, nutrigenetics 
and nutrigenomics, are subject to continuous advances reason why they are 
more and more useful in ophthalmology and sciences of the vision. 
Although DR and diabetic macular edema currently only have a palliative 
treatment that tries to prevent or slow vision loss, different diagnostic and 
therapeutic approaches are needed to combat diabetic blindness and its 
consequences for patients, families and the elderly society. We propose a 
multicentral study (Valencia Study) to analyse several clinical, biochemical, 
molecular and genetic aspects about DR, among them this subproject that 
aims to analyse the role of protein transport proteins of vitamins and 
molecules related to vascular risk with the availability of antioxidants and 
their implications for the presentation or progression of DR. 
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2. Objectives 
 
2.1. General:  
To study the relationship between plasma concentrations of folic acid, 
vitamin B12, Hcys, MDA, total TAS, GPx and the expression of genes 
related to these molecules in DM2 patients, and to analyse their 
correlation with the presentation and progression of DR in a 
Mediterranean population. 
 
2.2. Specifics: 
 
1. To explore the visual acuity and ocular fundus of the diabetic 
patients to characterize their DR. 
 
2. To analyse plasma concentrations of folic acid, vitamin B12 and 
Hcys in DM2 patients. 
 
3. To determine the expression of the following genes: SLC23A2, 
TP53, RBP1, MMP9, MMACHC, MMADHC, TMCO1 and 
THRA. 
 
4. To integrate the results of the clinic ophthalmology, 
biochemistry and genetics to establish a relationship between the 
ingestion and availability of these molecules. Including the 
expression of genes and the possible variations of these in 
relation to DM2. In order to clarify, if there is a need or not, for 
antioxidant supplementation. 
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5. To establish a new protocol and evaluate the need for 
micronutritional and antioxidant supplementation in DM2 
patients, and to curb the presentation or progression of DR and 
loss of vision. 
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MATERIALS AND METHODS 
 
 
1. Study design and participants 
We carried out a case-control study matched by age and gender, involving 
81 participants recruited from June to December 2012 at the University and 
Polytechnic Hospital La Fe, Dr. Peset University Hospital and Rahhal 
Clinic, according with the inclusion/exclusion criteria (Table 3). 
 
The sample size was calculated using the eNe 2.0 statistical program 
(GlaxoSmithKline S.A.) to get a statistical power of 80% and detect 
differences in the hypothesis contrast (Ho: p1=p2) using a bilateral χ2 test 
for two independent samples, considering that the level of significance 
would be 5%. 
 
All tests and study procedures were carried out in accordance with the 
Helsinki Declaration on Human Experimentation (Helsinki 1964, updated 
version 2004) and are in line with the current regulations for this type of 
studies in the European Community. 
 
The participants were informed about the details of the study and researchers 
explained to them the details of the study, giving them all details in a written 
document. Once they decided to participate, the informed consent was 
signed. Likewise, approval was obtained from the Ethics and Research 
Committees of the Dr. Peset University Hospital. 
 
 The following table shows the inclusion/exclusion criteria for the selection 
of participants: 
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The participants selected were classified into 2 groups: 
1. Patients with DM2 (n=49) 
2. Healthy controls (CTRL, n=32) 
 
Similarly, the DM2 group was subdivided into 2 other groups: 
1. Patients without DR (DM2-DR, n=35) 
2. Patients with DR (DM2+DR, n=14) 
 
Once an individual accepted to participate in the study, he/she was 
programmed for the ophthalmic examination and blood sample extraction.  
 
 
INCLUSION CRITERIA 
DM2 PATIENTS CONTROLS 
Age from 25 to 85 years Age from 25 to 85 years 
Suffer from DM2 at least 5 years ago Not having diabetes (type 1 or 2) 
Not suffering from systemic disease Not suffering from systemic disease 
EXCLUSION CRITERIA 
DM2 PATIENTS CONTROLS 
Age <25 or >85 years Age <25 or >85 years 
To have DM type 1 To have diabetes (type 1 or 2) 
Having any other eye disease that may 
interfere with the study 
Having any other eye disease that may 
interfere with the study 
(Table 3) Criteria for selecting the study participants 
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From each participant, 3 blood samples were extracted. One for the gene 
expression analysis, another one for several biochemical parameters and 
oxidative stress markers analysis and the last one for a simple blood 
analysis. This blood analysis included haematocrit, glycosylated 
haemoglobin, total cholesterol, HDL-cholesterol, LDL-cholesterol, 
triglycerides and folic acid, and was carried out at the department of Clinical 
Analysis of the centres participating in the study. 
 
The biochemical parameters and oxidative stress markers were analysed in 
plasma. For doing this, the blood sample was centrifuged at 2000 rpm during 
10 minutes at 4ºC. Then, the plasma was collected and aliquoted into 
cryotubes and stored at -80ºC. 
 
2. Ophthalmological exploration 
All patients underwent an ophthalmic examination of both eyes, which 
included: 
• Best corrected visual acuity (BCVA), with Snellen optotypes and 
expressed according to the decimal logarithm of angular size in 
minutes of arc (logMAR). 
• Complete biomicroscopy in slit lamp discarding ocular 
associated pathology and verifying that there was no 
contraindication for pupillary dilatation. 
• Goldmann applanation tonometer for intraocular pressure (IOP), 
estimated in millimetres of mercury (mmHg). 
• Funduscopy of the seven fields of DIABETIC. The assessment of 
the eye fund was carried out with slit lamp and lens of 78 
Diopters. In addition, retinographies were taken from each 
patient with TOPCON ImageNet TRC-50JA. 
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• The macular morphometric study was performed using spectral 
domain optical coherence tomography (HD-Cirrus, Carl Zeiss 
Meditec, Dublin, CA) 
The absence or presence of DR according to the characteristic funduscopic 
lesions was defined based on the DIABETIC study group (110): 
microaneurysms, haemorrhages, hard exudates, soft or cottony exudates, 
dilatation or venous tortuosity, intraretinal microvascular abnormalities 
(IRMAS) and/or neovascularization. Depending on these signs, we classify 
DR patients according to the early treatment diabetic retinopathy study 
(ETDRS). 
3. Study of classic biomechanical parameters  
The biochemical parameters assayed were: total protein concentration, CRP, 
vitamin B12 and Hcys. 
All these parameters were assayed by duplicate. 
 
3.1. Total protein concentration 
Total protein determination was performed using the bicinchoninic acid 
(BCA) technique, using the Bicinchoninic Acid Protein Assay Kit 
(BCA1 and B9643, Sigma-Aldrich). It is a method similar to that of 
Lowry (111), and is based on the formation, under alkalinity conditions, 
of a Cu2+-protein complex, followed by a reduction of Cu2+ to Cu1+. 
Then, the BCA reacts with the reduced copper to form a compound that 
absorbs light at 560 nm, which can be measured by spectrophotometry 
(112-117). 
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The kit includes the following reagents:  
 
• Reagent A: contains BCA, sodium carbonate, sodium tartrate and 
sodium bicarbonate in 0.1N sodium hydroxide (pH = 11.25) 
• Reagent B: contains 4% (w/v) copper (II) sulphate pentahydrate. 
• Protein Standard: 1.0 mg/mL BSA (bovine serum albumin) in 
0.15M sodium chloride, with 0.05% sodium acid as preservative. 
 
From the protein standard, we must prepare serial dilutions of different 
concentrations of BSA. The way to prepare these standards is shown in the 
following table. 
 
 
(Table 4) Preparation of BSA standard. 
 
 
 
 
 
 
 
 
# (BSA) µg/mL BSA Volume (mL) H2O Volume (mL) 
1 1000 75 0 
2 800 60 15 
3 600 45 30 
4 400 30 45 
5 200 15 60 
6 0 0 75 
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In the same way, we must prepare a solution with reagents A and B, mixing 
50 parts of reagent A with 1 part of reagent B. Once the solution A + B and 
the standards are prepared, we carry out the analysis, on a 96-well plate, as 
follows: 
 
• Add 25 µL standard/sample to the corresponding wells. 
• Add 200 µL of solution A+B to each well. The relationship between 
this volume and the volume of the previous step must be 8:1. 
• Incubate 1 hour at 60°C. 
• Measure the absorbance at 562 nm (545-590 nm filters can be used). 
 
We draw the standard curve (absorbance vs. concentration of BSA, figure 9) 
and, from this, we will calculate the total protein concentration in each of the 
samples, considering the dilution factor (in case we have had to dilute the 
sample). 
 
(Figure 9) Standard curve example of the bicinchoninic acid assay for protein analysis. 
Taken from the booklet included in the SIGMA kit, code BCA1 and B9643. 
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3.2. C reactive protein 
The determination of plasma levels of CRP was performed using the 
CRP Human ELISA Kit (KHA0031, Thermo Fisher). 
 
The reagents included in the kit were: 
• Hu CRP Standard 
• Standard Diluent Buffer 
• Antibody Coated Wells 
• Hu CRP Biotin Conjugate 
• Streptavidin-HRP (100X) 
• Streptavidin HRP Diluent 
• Wash Buffer Concentrate (25X) 
• Stabilized Chromogen (tetramethylbenzidine – TMB) 
• Stop Solution 
 
To prepare the standard curve, we followed the manual as 
follows: 
• Reconstitute Hu CRP Standard to 8000 pg/mL with 
Standard Diluent Buffer.  
• Add 300µL of reconstituted standard to a tube containing 
1700µL of Standard Diluent Buffer, mix and label as 1200 
pg/mL (STD1). 
• Follow the serial dilutions as is showed in the next figure: 
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(Figure 10) Preparation of the standard curve, obtained from the manual of the kit. 
 
Before starting with the protocol, we also have to prepare the 
samples. Human plasma requires, at least, a 3000–fold dilution in the 
Standard Diluent Buffer. 
 
Once the standard and samples are prepared, we proceed with the 
assay: 
 
• Add 100µL of Standard Diluent Buffer to the zero standard 
wells. The wells reserved for the chromogen blank should be left 
empty. 
• Add 100µL of standards and diluted samples to the 
corresponding wells. 
• Cover the plate and incubate for 2 hours at 37ªC. 
• Remove the solution and wash the wells 4 times with diluted 
Wash Buffer. 
• Add 100µL Hu CRP Biotin Conjugate to all wells, except those 
for the chromogen blanks. 
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• Cover the plate and incubate for 1 hour at RT. 
• Remove the solution and wash the wells 4 times with diluted 
Wash Buffer. 
• Add 100µL of 1X Streptavidin-HRP into each well, except 
chromogen blanks. 
• Cover the plate and incubate for 30 minutes at RT. 
• Remove the solution and wash the wells 4 times with diluted 
Wash Buffer. 
• Add 100µL of Stabilized Chromogen to each well (the substrate 
solution will begin to turn blue). 
• Incubate 30 minutes at RT in dark. 
• Add 100µL of Stop Solution to each well (the colour will change 
from blue to yellow) 
• Read the absorbance at 450nm within 30 minutes after adding 
the stop solution. 
 
3.3. Vitamin B12 
The plasma determination of this vitamin was carried out by means of 
the Vitamin B12 ELISA Kit (KA1170, Abnova).  
The microtiter plate provided in this kit has been pre-coated with an 
antibody specific to Vitamin B12. During the reaction, Vitamin B12 in 
the sample or standard competes with a fixed amount of biotin-labelled 
Vitamin B12 for sites on a pre-coated Monoclonal antibody specific to 
Vitamin B12. Excess conjugate and unbound sample or standard are 
washed from the plate. Next, Avidin conjugated to Horseradish 
Peroxidase (HRP) is added to each microplate well and incubated. Then 
a TMB substrate solution is added to each well. The enzyme-substrate 
reaction is terminated by the addition of a sulphuric acid solution and 
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the colour change is measured spectrophotometrically at a wavelength of 
450 nm ± 2 nm. The concentration of Vitamin B12 in the samples is 
then determined by comparing the O.D. of the samples to the standard 
curve. 
 
To make the experiments, the reagents used were: 
 
1. Stock Standard 
2. Sample Diluent 
3. Assay Diluent (A and B) 
4. Detection Reagent (A and B) 
5. Wash Buffer 
6. Substrate Solution 
7. Stop Solution 
 
The first step was to prepare the standard curve. The Stock Standard was 
diluted with Sample Diluent in order to produce a solution of 1000 
pmol/L. Then, this solution was used for making serial dilutions with 
Sample Diluent, which serves as the zero standard (0 pmol/L). 
 
  
 
 
Standard 
 
pmol/L 
A 
 
1000 
B 
 
500 
C 
 
250 
D 
 
125 
E 
 
62.5 
F 
 
31.2 
G 
 
1.56 
H 
 
0 
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The assay procedure was as follows: 
 
• Add 50 µl of Standard, Blank, or Sample per well. 
• Immediately add 50 µl of Detection Reagent A working solution to each 
well. Cover with the Plate sealer. Tap the plate and incubate for 1 hour at 
37°C. 
• Aspirate each well and wash (total 3 washes) by filling each well with 
400µL of Wash Buffer. After the last wash, remove any remaining Wash 
Buffer by aspirating or decanting. Invert the plate and blot it against 
clean paper towels. 
• Add 100 µL of Detection Reagent B working solution to each well. 
Cover with a new plate sealer and incubate for 45 minutes at 37°C. 
• Repeat the aspiration/wash process for five times as conducted in step 3. 
• Add 90 µL of Substrate Solution to each well. Cover with a new plate 
sealer and incubate within 15-30 minutes at 37°C.  Important: protect from 
light. 
• Add 50 µL of Stop Solution to each well. 
 
Measure the optical density of each well at once, using a microplate reader 
set to 450 nm. 
 
In order to calculate the vitamin B12 concentration in samples, we had to 
create a standard curve using computer software capable of generating a 
four-parameter logistic (4-PL) curve-fit.  
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3.4. Homocysteine 
The determination of plasma levels of Hcys was performed using the 
Hcys ELISA Kit (STA-670, Cell Biolabs) and the reagents included in 
the kit were: 
 
• Anti-Hcys Antibody. 
• Secondary Antibody, HRP Conjugate. 
• Assay Diluent (Part No. 310804): One 50 mL bottle. 
• 10X Wash Buffer. 
• Hcys Conjugate. 
• Hcys -BSA Standard. 
• Substrate Solution. 
• Stop Solution. 
 
To prepare the standard curve we followed the manual from the kit. 
See table 5 
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(Table 5) Standard curve preparation for homocysteine assay 
 
After the standard preparation, we proceeded with the assay as follows: 
 
• Remove the Assay Diluent from the plate and add 50 µL of 
unknown sample or standard to the Hcys Conjugate Coated Plate. 
Incubate at RT for 10 minutes on an orbital shaker. 
• Add 50 µL of diluted Anti- Hcys Antibody to each well.  Incubate 
at RT for 1 hour on an orbital shaker. 
• Wash microwell strips 3 times with 250 µL 1X Wash Buffer per 
well with thorough aspiration between each wash. After each wash, 
empty wells and tap microwell strips on absorbent paper towel to 
remove excess 1X Wash Buffer. 
• Add 100 µL of the diluted Secondary Antibody, HRP Conjugate to 
each well. Incubate at RT for 1 hour on an orbital shaker.  
 
Standard 
Tubes 
4 mg/mL 
Homocysteine-BSA 
Standard (µL) 
Assay 
Diluent 
(µL) 
Homocysteine-BSA 
(µg/mL) 
1 4 396               40 
2 100 of Tube #1 300               10 
3 100 of Tube #2 300 2.5 
4 100 of Tube #3 300 0.625 
5 100 of Tube #4 300 0.156 
6 100 of Tube #5 300 0.039 
7 100 of Tube #6 300 0.010 
8 0 300                0 
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• During this incubation, warm Substrate Solution to RT. 
• Wash the strip wells 3 times according to step 5 above.  Proceed 
immediately to the next step. 
• Add 100 µL of Substrate Solution to each well, including the blank 
wells. Incubate at RT on an orbital shaker. 
• Stop the enzyme reaction by adding 100 µL of Stop Solution into 
each well, including the blank wells.  Results should be read 
immediately (colour will fade over time). 
• Read absorbance on a spectrophotometer using 450 nm as the 
primary wave length. 
 
 
4. Oxidative stress 
We analysed the plasma concentration of MDA, marker of oxidative 
damage), plasma levels of GPx (GSH, an antioxidant enzyme) and the 
plasma Total TAS. 
 
 All samples were assayed by duplicate. 
 
4.1. Determination of lipoperoxidative activity (MDA/TBARS) 
The measurement of MDA as a product of lipid peroxidation is carried 
out following the technique of thiobarbituric acid and its reactive species 
(TBARS) (118-120). 
 
The aldehyde group of MDA reacts with two molecules of thiobarbituric 
acid (TBA) at acidic pH and high temperature (approximately 100°C) to 
form a pink complex, which is extracted with butanol. The fluorescence 
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of this complex is measured and compared with the standard ones 
(standard curve) to calculate the MDA concentration in samples. 
 
 
(Figure 11) Reaction between malondialdehyde and thiobarbituric acid. Source: Northwest 
Life Science Specialties L.L.C 
 
The reagents used were: 
• MDA (1,1,3,3-Tetraethoxypropane) 
• Phosphate buffered saline (PBS) 
• Sodium Dodecil Sulfate (SDS) 
• Chlorhydric acid (HCl) 
• Phosphotungstic acid 
• Thiobarbituric acid (TBA) 
• N-butanol 
 
 
 
 
MDA              TBA                               MDA-TBA2 
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First, we had to prepare the standards, following the indications showed 
in the next table: 
 
 
After this, we proceed as follows: 
 
• Add 250µL of standard / diluted sample into the appropriate tubes. 
• Add 125 µL of PBS buffer. 
• Add 100µL of 7% SDS. 
• Add 1mL of 0.1N HCl. 
• Add 150µL of 1% phosphotungstic acid. 
• Add 500µL of 0.67% TBA. 
• Shake the tubes and boil in the bath for 1 hour at 98°C (protect from 
light). 
 MDA (µM) VMDA (µL) VPBS (µL)* 
P1 0 0 60 
P2 1 30 30 
P3 3 9 51 
P4 5 15 45 
P5 10 30 30 
* 0.01M PBS 
(Table 6) Preparation of standard curve 
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• Cool the tubes with ice for about 10 minutes. 
• Add 1mL of n-butanol. 
• Centrifuge at 2800 rpm for 10 min at room temperature (RT). 
• Add 200µL of the supernatant to the appropriate well of the plate. 
• Measure the fluorescence at 544nm excitation and 590nm emission, 
using the Fluoroskan Ascent FL (Termo Electron Corp., Waltham, 
MA, USA). 
 
4.2. Determination of total antioxidant status (TAS) 
The plasma levels of TAS was determined using the Antioxidant Assay 
Kit (709001, Cayman Chemical), which relies on the ability of 
antioxidants to inhibit the oxidation of 2,2’-Azino-di-3-
ethylbenzthiazoline sulphonate (ABTS) to ABTS·+ by metmyoglobin. 
The amount produced of this cation is inversely proportional to the 
antioxidants present in samples, and it can be monitored by reading the 
absorbance at 750 nm. 
 
The reagents needed for the determination of TAS are: 
 
• Phosphate buffered saline (PBS). 
• ABTS® chromogen (2,2 azino-bis-(3-etilbenzotiazolina-6-
sulfonato)) 
• Metmyoglobin 
• Trolox (6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid). 
• Substrate (hydrogen peroxyde - H202) 
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First, we had to prepare the standard curve, following the instructions of 
the manual. 
 
(Table 7) Standard preparation for determining the total antioxidant status 
Once standards and samples are ready to be processes, the procedure is 
as follows: 
1. Add 10µL of standard / sample to the corresponding well 
2. Add 10µL of metmyoglobin and 150µL of chromogen per well. 
3. Initiate the reactions by adding 40µL of H2O2 working solution to the 
wells, as quickly as possible. 
4. Cover the plate and incubate on a shaker for 5 minutes at RT. 
5. Remove cover and read absorbance at 750nm. 
 
 
 
Standard (STD) Trolox (µL) Assay Buffer (µL) 
Final conc. 
(mM Trolox) 
A 0 1000 0 
B 30 970 0.044 
C 60 940 0.088 
D 90 910 0.135 
E 120 880 0.180 
F 150 850 0.225 
G 220 780 0.330 
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(Figure 12) Example of standard curve for total antioxidant status assay. Source: manual of Antioxidant 
Assay Kit (709001, Cayman Chemical) 
 
4.3. Determination of glutathione peroxidase activity (GPx) 
The determination of the GPx activity was performed using the GPx 
Assay Kit (703102, Cayman Chemical), which measures the GPx 
activity indirectly by a coupled reaction with glutathione reductase 
(GR): 
 
 
 
This process is accompanied by a decreasing in absorbance at 340nm. 
 
 
 
 
ROOH + 2GSH                            ROH + GSSG + H2O
GSSG + NADPH + H+ 2GSH + NADP +
GPx
GR
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The reagents used in this protocol were: 
 
1. GPx Assay Buffer (10X) 
2. GPx Sample Buffer (10X) 
3. Glutathione Peroxidase (positive control) 
4. GPx Co-Substrate Mixture 
5. GPx Cumene Hydroperoxide 
 
 
The next steps to determine the GPx activity were: 
 
1. Add 120µL of Assay Buffer and 50µL of Co-Sustrate Mixture to the 
background wells. 
2. Add 100µL of Assay Buffer, 50µL of Co-Sustrate Mixture and 
20µL of diluted GPx (control) to the positive control wells. 
3. Add 100µL of Assay Buffer, 50µL of Co-Sustrate Mixture and 
20µL of diluted GPx (control) to the sample wells.  
4. Add 20µL of Cumene Hydroperoxide to all the wells and shake the 
plate carefully during a few seconds. 
5. Read the absorbance on every minute at 340nm to obtain at least 5 
time points. 
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After reading the absorbance, use the next equation to calculate the change 
in absorbance per minute: 
 
GPx activity  =  
ΔA340/min. x 0,19 ml x  sample dilution = nmol/min/ml 
0,00373 µM–1 0,02 ml 
 
 
Determine the rate ΔA340/min for the background, subtract this rate from that 
of the sample wells and use the following formula to calculate the GPx 
activity: 
 
ΔA340/min.  =    
*│A340 (Time 2) – A340 (Time 1) │ 
Time 2 (min.) – Time 1 (min.) 
 
 
5. Gene expression analysis 
We studied the expression of 8 genes: SLC23A2, TP53, RBP1, MMP9, 
MMACHC, MMADHC, TMCO1, THRA. 
The gene expression analysis was carried out in the laboratory of the 
department of Preventive Medicine & Public Health of the School of 
Medicine (University of Valencia). 
 
5.1. Extraction and quantification of RNA 
1. Let the blood tubes rest between 60-120 minutes, so that the serum 
is separated by sedimentation.  
2. Transfer the serum to a 15 mL sterile plastic tube, avoiding to take 
anything from the interface.  
3. Centrifuge at 1500-2000 rpm for 15 minutes. 
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4. Remove the supernatant by decantation; fill the tube with PBS and 
vortex to resuspend the pellet. 
5. Centrifuge at 1500-2000 rpm for 15 minutes.  
6. Remove the supernatant by decantation and add 500-1000 µL of 
Trizol, depending on the size of the pellet. 
7. Mix well with the vortex until the pellet dissolves completely in the 
Trizol. 
8. Transfer by decantation to a 1.5 mL eppendorf tube. 
9. Freeze the tubes at -80 oC and continue the protocol the next day. 
 
 
(Figure 13) Centrifuge used for RNA extraction. 
 
1. Homogenize the samples, once thawed, to ensure the rupture of the cells. 
2. Transfer to a 2 mL tube. 
3. Add 200 µl of chloroform if we started with 1000 µL of trizol (100 µL if 
we did with 500 µL of trizol). 
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4. Mix by inversion. 
5. Let stand for 2-3 minutes. 
6. Centrifuge at 13000 rpm for 15 minutes. When the centrifuge is 
finished, we can observe three phases in the tubes: 
 
(Figure 14) Separation of the RNA after centrifugation 
 
1. While centrifuging, prepare and label one eppendorf per sample. 
2. Pipette as much of the aqueous phase as possible, without taking any of 
the interface or the organic phase. 
3. Add 500 µL of isopropanol. 
4. Add 2 µL of glycogen. 
5. Shake the tubes manually and leave them at -20oC overnight. 
6. Remove from the freezer and centrifuge at 13000 rpm for 15 minutes. 
7. Remove the supernatant completely (by decantation and with pipette). 
8. Add 500 µL of cold 75% EtOH. 
9. Vortex for 3 seconds. 
10. Centrifuge at 13000 rpm and 4oC for 15 minutes.  
11. Remove EtOH with pipette and remaining, by stoving at 37oC for a 
couple of minutes. 
	
 
 
78 
 
12. Resuspend the pellet in 20 µL of H2O PCR quality. 
13. Quantify the RNA by spectrophotometry (NanoPhotometer, Implen 
GmbH, Schatzbogen 52, D-81829, Germany). 
14. Store RNA into the freezer at -70oC 
 
5.2. Obtaining and quantifying complementary DNA (cDNA) 
To perform the conversion of RNA to cDNA we used the High Capacity 
RNA to cDNA kit (Applied Biosystems, Foster City, CA, USA), whose 
protocol is as follows: 
 
A. We used 300ng of RNA from each sample, and we followed the 
indications of the manufacturer to continue the protocol. 
 
(Table 8) Products, volume and concentration in High Capacity RNA to cDNA kit 
 
 
 
 
 
 
 
 
Product Volume per sample 
Final 
concentration 
Master mix 4 µL 1X 
RNA Max - 16 µL 1 pg – 1 µg 
H2O (nuclease-free) Until 20 µL  
Total 20 µL  
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B. PCR: 
 
 
(Table 9) PCR protocol for the High Capacity RNA to cDNA kit 
 
At the end of this protocol, the quantification of the samples was performed 
by spectrophotometry (NanoPhotometer, Implen GmbH, Schatzbogen 52, D-
81829, Germany) 
 
(Figure 15) Spectrophotometer 
 
5.3. Gene expression analysis 
Using Taqman probes and a real-time thermalcycler (7900HT Fast Real-
Time Thermalcycler, Applied Biosystems, Foster City, CA, USA). 
 
We used 2 probes for each assay: the probe of the gene from which we 
want to analyze the expression (target gene), and a probe of a 
normalizing gene or housekeeping (specifically, the GAPDH gene was 
used as normalizer). 
 Phase 1 Phase 2 Phase 3 Phase 4 
Temperature (oC) 25 42 85 4 
Time 5 min 30 min 5 min ∞ 
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The protocol carried out wasas follows: 
 
1. Prepare 2 reaction mixtures (one with the target gene probe and one with 
the normalizing gene probe) with the following volumes per sample: 5 
µL of master mix, 0.5 µL of probe and 3.5 µL of H2O (total volume = 9 
µL).  
2. Prepare 2 reaction mixtures (one with the target gene probe and one with 
the normalizing gene probe) with the following volumes per sample: 5 
µL of master mix, 0.5 µL of probe and 3.5 µL of H2O (total volume 9 
µL) . 
3. We perform the test by duplicate. 
4. Add 9 µL of the reaction mixture to the target/housekeeping wells of the 
96-well plate, spin the plate for 5 seconds and add 1 µL of cDNA into 
each well. 
5. Seal the plate with an adhesive and spin for 5 seconds. 
6. PCR Protocol:: 
• 2 minutes at 50ºC 
• 10 minutes at 95ºC 
• 15 seconds at 95ºC 
• 1 minute and 25 seconds at 60ºC 
7. Repeat the last two steps in 50 cycles. 
To calculate the relative expression, the following equation was used:  
𝑅𝑄 =  2−∆∆𝐶𝑡 	
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The first ΔCt was: Cttarget - Cthousekeeping 
The second ΔCt was: 1st ΔCt – (average of Cthousekeeping from control samples) 
To represent the fold change of gene expression, the mean of gene 
expression in all the study groups (controls, DM2, DM-DR, DM+DR) was 
divided by the mean of gene expression of CTRL. 
 
6. Statistical analysis 
The data were processed to descriptive statistical analysis with the IBM 
SPSS Statistics for Windows 22.0 program (IBM Corp., Armonk, NY, 
USA). 
 
The normality of the quantitative variables was checked by the Kolmogorov-
Smirnov test. The categorical variables were compared using the Pearson 
Chi-square test. 
 
The comparison of 2 means was performed using Student's t-test for normal 
variablles or the Mann-Whitney U test for non-normal variables. The 
comparison of more than two means was performed by analysis of variance 
(ANOVA) for normal variables or by the Kruskal-Wallis test for non-normal 
variables. 
 
The Pearson correlation coefficient (normal variables) and Spearman's Rho 
coefficient (non-normal variables) were used to determine the magnitude of 
association of 2 quantitative variables. 
All statistical analysis were performed assigning a significance level of 0.05. 
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RESULTS 
 
 
1. Basic characteristics of groups and subgroups  
81 participants were included in this study from both sexes, between ages 
26-82 years old. These were divided in two groups consisting of a control 
group (CTRL) (n = 32) and a DM2 group (DM2-G) (n = 49).  
The DM2 group has two subgroups consisting of participating with DR 
(DM2+DR) (n = 14, 28,6%) and without DR (DM2-DR) (n = 35, 71,4%).  
Participants have also been divided into groups consisting of a younger 
group (age from 25-55) and an older group (age from 56-85). 
 
2. Ophthalmic results 
The results of the quantitative variables best corrected visual acuity 
(BCVA), intraocular pressure (IOP) and optical coherence tomography 
(OCT) are expressed as average ± standard deviation of right eye (RO) and 
left eye (LO). The results of the qualitative variables are expressed in 
percentage and frequency of RO and LO. All these data are reflected in 
following tables. 
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Ophthalmic parameter CTRL DM2 p 
BCVA 
RO 1,000 0,780 0,000* 
LO 1,036 0,730 0,000* 
IOP (mmHg) 
RO 14,0 15,2 0,786 
LO 15,0 15,3 0,950 
OCT (µm) 
RO 248,1 259,8 0,299 
LO 248,6 272,7 0,393 
 
(Table 10) Differences in ophthalmic parameters between control and DM2 groups  
 
CTRL: control group; DM2: diabetes mellitus type 2 group; BCVA: best corrected visual acuity; 
IOP: intraocular pressure; OCT: optical coherence tomography; RO: Right orbit; LO: Left orbit 
* statistically significant (p<0,05)   
 
 
 
 
 
Ophthalmic parameter CTRL DM-DR DM+DR p 
BCVA 
RO 1,000 0,843 0,663 0,000* 
LO 1,036 0,798 0,598 0,000* 
IOP (mmHg) 
RO 14,0 14,2 16,1 0,610 
LO 15,0 14,8 15,8 0,886 
OCT (µm) 
RO 248,1 247,4 290,3 0,014* 
LO 248,6 262,5 299,3 0,280 
 
(Table 11) Differences in ophthalmic parameters between control and DM2 without/with diabetic 
retinopathy  
 
CTRL: control group; DM2-DR: diabetes mellitus type 2 without diabetic retinopathy; DM2+DR: 
diabetes mellitus type 2 with diabetic retinopathy; BCVA: best corrected visual acuity; IOP: 
intraocular pressure; OCT: optical coherence tomography; RO: Right orbit; LO: Left orbit 
* Statistically significant (p<0,05) 
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3. Classical biochemistry 
3.1. Different molecules  
 
Molecule CTRL DM2 p 
Glu (mg/dL) 83,3 127,6 7,18E-7* 
Hct (%) 43,6 41,7 0,179 
HbA1c (%) 5,5 7,0 6,43E-12* 
FA (ng/mL) 8,2 10,3 0,135 
 
(Table 12) Difference in plasma levels of different molecules between control and DM2 groups  
 
CTRL: control group; DM2: diabetes mellitus type 2 group; Glu: glucose; Hct: haematocrit; HbA1c: glycosylated 
haemoglobin; FA: folic acid 
* Statistically significant (p<0,05)  
 
 
 
 
 
Molecule 
MALE 
p 
FEMALE 
p 
CTRL DM2 CTRL DM2 
Glu (mg/dL) 85,13 + 4.09 119,61 (5,02) 0,009* 81,6 138,2 2,21E-7* 
Hct (%) 44,9 43,0 0,070 41,0 40,2 0,762 
HbA1c (%) 5,6 7,2 0,000 5,5 6,9 2,07E-6* 
FA (ng/mL) 7,8 9,3 0,259 8,6 11,4 0,345 
 
(Table 13) Difference in plasma levels of different molecules between control and DM2 groups by age  
 
CTRL: control group; DM2: diabetes mellitus type 2 group; Glu: glucose; Hct: haematocrit; HbA1c: glycosylated 
haemoglobin; FA: folic acid 
* Statistically significant (p<0,05)     
The results are expressed as mean (standard deviation) 
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Molecule 
MALE 
p 
FEMALE 
p 
CTRL DM-DR DM+DR CTRL DM-DR DM+DR 
Glu (mg/dL) 85,1Þ 134,7 82,0Þ 0,006* 81,6 138,8§ 136,8§ 1,81E-6* 
Hct (%) 44,9 43,1 42,8 0,402 41,0 40,9 39,1 0,692 
HbA1c (%) 5,6 7,2§ 6,9§ 0,0002* 5,5 6,9§ 6,8§ 0,00001* 
FA (ng/mL) 7,8 8,9 10,9 0,249 8,6 9,8 15,2 0,223 
 
(Table 14) Difference in plasma levels of different molecules between controls and DM2 without/with diabetic 
retinopathy by gender  
 
CTRL: control group; DM-DR: diabetes mellitus type 2 without diabetic retinopathy; DM+DR: diabetes mellitus 
type 2 with diabetic retinopathy; Glu: glucose; Hct: haematocrit; HbA1c: glycosylated haemoglobin; FA: folic acid 
* Statistically significant (p<0,05)       
Þ Significant differences respect to the DM-DR group      
§ Significant differences respect to the control group      
 
 
 
 
Molecule 
YOUNG GROUP 
p 
OLD GROUP 
p 
CTRL DM2 CTRL DM2 
Glu (mg/dL) 79,2 137,5 0,055 88,6 125,7 0,00003* 
Hct (%) 44,1 45,0 0,540 42,5 41,0 0,509 
HbA1c (%) 5,5 7,2 0,014* 5,6 7,0 5,62E-9* 
FA (ng/mL) 6,9 8,9 0,156 8,9 10,6 0,933 
 
(Table 15) Difference in plasma levels of different molecules between control and DM2 groups by age  
 
CTRL: control group; DM2: diabetes mellitus type 2 group; Glu: glucose; Hct: haematocrit; HbA1c: 
glycosylated haemoglobin; FA: folic acid 
* Statistically significant (p<0,05)     
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3.2. Total protein concentration 
(Chart 1) Total protein concentration (g/dL) 
(Chart 2) Total protein concentration (g/dL) by age 
(Chart 3) Total protein concentration (g/dL) by gender 
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3.3. C reactive protein 
(Chart 4) C Reactive Protein (mg/L) 
(Chart 5) C Reactive Protein (mg/L) by gender 
3.4. Homocysteine 
(Chart 6) Homocysteine (µmol/L) 
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(Chart 7) Homocysteine (µmol/L) by gender 
3.5. Vitamin B12 
(Chart 8) Vitamin B12 (pg/mL) 
(Chart 9) Vitamin B12 (pg/mL) in women 
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3.6. Lipids 
 
Lipid CTRL DM2 p 
T-Ch (mg/dL) 209,4 183,6 0,004* 
HDL-Ch (mg/dL) 66,2 49,4 0,000* 
LDL-Ch (mg/dL) 129,1 104,5 0,001* 
TG (mg/dL) 87,6 153,8 0,000* 
(Table 16) Difference in plasma lipid levels between control and DM2 groups  
CTRL: control group; DM2: diabetes mellitus type 2 group; T-Ch: total cholesterol; HDL-Ch: HDL 
cholesterol; LDL-Ch: LDL cholesterol; TG: triglycerides 
* Statistically significant (p<0,05)  
  
Lipid 
MALE 
p 
FEMALE 
p 
CTRL DM2 CTRL DM2 
T-Ch (mg/dL) 218,8 182,1 0,010* 200,6 185,3 0,162 
HDL-Ch (mg/dL) 57,5 44,3 0,015* 74,9 55,2 0,004* 
LDL-Ch (mg/dL) 141,9 106,0 0,001* 116,4 102,9 0,188 
TG (mg/dL) 100,5 169,6 0,006* 75,6 134,9 0,001* 
 
(Table 17) Differences in plasma lipid levels between control and DM2 groups by gender  
CTRL: control group; DM2: diabetes mellitus type 2 group; T-Ch: total cholesterol; HDL-Ch: HDL 
cholesterol; LDL-Ch: LDL cholesterol; TG: triglycerides 
* Statistically significant (p<0,05)     
 
Lipid 
YOUNG GROUP 
p 
OLD GROUP 
p 
CTRL DM2 CTRL DM2 
T-Ch (mg/dL)     214,5 212,9 0,940 202,2 178,2 0,017* 
HDL-Ch (mg/dL) 60,3 50,3 0,495 75,6 49,2 0,003* 
LDL-Ch (mg/dL) 138,0 121,1 0,350 115,2 101,2 0,093 
TG (mg/dL) 89,1 211,7 0,041* 89,6 142,9 0,004* 
 
(Table 18) Differences in plasma lipid levels between control and DM2 groups by age  
CTRL: control group; DM2: diabetes mellitus type 2 group; T-Ch: total cholesterol; HDL-Ch: HDL 
cholesterol; LDL-Ch: LDL cholesterol; TG: triglycerides 
* Statistically significant 
(p<0,05) 
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3.7. Oxidative stress 
(Chart 10) Oxidative stress markers 
 
 
(Chart 11) Oxidative stress by gender 
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(Chart 12) Oxidative stress by age 
 
4. Molecular biochemistry of diabetic retinopathy  
4.1. Different molecules  
 
Molecule CTRL DM-DR DM+DR p 
Glu (mg/dL) 83,3 136,4
§ 105,5 7,22E-6* 
Hct (%) 43,6 42,2 40,7 0,243 
HbA1c (%) 5,5 7,1
§ 6,9§ 3,36E-9* 
FA (ng/mL) 8,2 9,3 13,3 0,059 
 
(Table 19) Differences in plasma levels of different molecules between controls and DM2 without/with 
diabetic retinopathy  
 
CTRL: control group; DM-DR: diabetes mellitus type 2 without diabetic retinopathy; DM+DR: diabetes 
mellitus type 2 with diabetic retinopathy; Glu: glucose; Hct: haematocrit; HbA1c: glycosylated 
haemoglobin; FA: folic acid 
* Statistically significant (p<0,05)   
§ Significant differences respect to the control group  
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(Chart 13) Total Protein Concentration (g/dL) by gender 
(Chart 14) C Reactive Protein (mg/L) by gender 
(Chart 15) Homocysteine (µmol/L) by gender 
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(Chart 16) Vitamin B12 (pg/mL) in women 
 
4.2. Lipids 
 
Lipid CTRL DM-DR DM+DR p 
T-Ch (mg/dL) 209,4 184,4 181,0 0,015* 
HDL-Ch (mg/dL) 66,2 48,8 51,4 0,001* 
LDL-Ch (mg/dL) 129,1 103,3 108,4 0,005* 
TG (mg/dL) 87,6 162,0 129,4 0,000* 
 
(Table 20) Differences in plasma lipid levels between controls and DM2 without/with diabetic retinopathy  
 
CTRL: control group; DM-DR: diabetes mellitus type 2 without diabetic retinopathy; DM+DR: diabetes mellitus 
type 2 with diabetic retinopathy; T-Ch: total cholesterol; HDL-Ch: HDL cholesterol; LDL-Ch: LDL cholesterol; 
TG: triglycerides 
* Statistically significant (p<0,05) 
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Lipid 
MALE 
p 
MALE 
p 
CTRL DM-DR DM+DR CTRL DM-DR DM+DR 
T-Ch (mg/dL) 218,8 181,2§ 185,6 0,037* 200,6 188,5 177,2 0,295 
HDL-Ch (mg/dL) 57,5 43,5§ 47,4 0,028* 74,9 55,4§ 54,7§ 0,017* 
LDL-Ch (mg/dL) 141,9 102,8§ 120,3 0,003* 116,4 103,9 100,5 0,414 
TG (mg/dL) 100,5 173,6
§ 154,4§ 0,025* 75,6 146,2§ 108,5 0,002* 
 
(Table 21) Differences in plasma lipid levels between controls and DM2 without/with diabetic retinopathy by 
gender  
 
CTRL: control group; DM-DR: diabetes mellitus type 2 without diabetic retinopathy; DM+DR: diabetes mellitus 
type 2 with diabetic retinopathy; T-Ch: total cholesterol; HDL-Ch: HDL cholesterol; LDL-Ch: LDL cholesterol; 
TG: triglycerides 
* Statistically significant (p<0,05)       
§ Significant differences respect to the control group    
 
4.3. Oxidative stress 
(Chart 17) Oxidative stress markers 
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(Chart 18) Oxidative stress by gender 
 
5. Genetics of diabetic retinopathy 
5.1.  Relative expression of SLC23A2 gene 
 
 
 
 
 
 
 
(Chart 19) Relative expression of SLC23A2 gene (p=0.026) 
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(Chart 20) Relative expression of SLC23A2 gene by gender (male: p=0.019; female: 
p=0.061) 
 
 
 
 
 
(Chart 21) Relative expression of SLC23A2 gene by age (young: p=0.047; old: p=0.027) 
 
5.2.  Relative expression of TP53 gene 
(Chart 22) Relative expression of TP53 gene (p=0.084) 
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(Chart 23) Relative expression of TP53 gene by gender (male: p=0.350; female: p=0.456) 
(Chart 24) Relative expression of TP53 gene by age (young: p=0.442; old: p=0.234) 
 
5.3. Relative expression of RBP1 gene 
(Chart 25) Relative expression of RBP1 gene (p=0.612) 
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(Chart 26) Relative expression of RBP1 gene by gender (male: p=0.748; female: p=0.682) 
(Chart 27) Relative expression of RBP1 gene by age (young: p=0.694; old: p=0.117) 
 
5.4.  Relative expression of MMP9 gene 
 
 
 
 
 
(Chart 28) Relative expression of MMP9 gene (p=0.036) 
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(Chart 29) Relative expression of MMP9 gene by gender (male: p=0.058; female: 
p=0.010) 
 
 
 
 
 
(Chart 30) Relative expression of MMP9 gene by age (young: p=0.006; old: p=0.039) 
 
5.5. Relative expression of MMACHC gene 
(Chart 31) Relative expression of MMACHC gene (p=0.517) 
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(Chart 32) Relative expression of MMACHC gene by gender (male: p=0.884; female: 
p=0.267) 
(Chart 33) Relative expression of MMACHC gene by age (young: p=0.280; old: p=0.738) 
 
5.6.  Relative expression of MMADHC gene 
(Chart 34) Relative expression of MMADHC gene p=0.120) 
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(Chart 35) Relative expression of MMADHC gene by gender (male: p=0.164; female: 
p=0.294) 
(Chart 36) Relative expression of MMADHC gene by age (young: p=0.399; old: p=0.822) 
 
5.7. Relative expression of TMCO1 gene 
(Chart 37) Relative expression of TMCO1 gene (p=0.492) 
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(Chart 38) Relative expression of TMCO1 gene by gender (male: p=0.232; female: 
p=0.745) 
(Chart 39) Relative expression of TMCO1 gene by age (young: p=0.540; old: p=0.346) 
5.8.  Relative expression of THRA gene 
(Chart 40) Relative expression of THRA gene (p=0.455) 
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(Chart 41) Relative expression of THRA gene by gender (male: p=0.859; female: p=0.342) 
(Chart 42) Relative expression of THRA gene by age (young: p=0.281; old: p=0.363) 
6. Relative gene expression with diabetes retinopathy 
6.1.  Relative expression of SLC23A2 gene 
(Chart 43) Relative expression of SLC23A2 gene (p=0.018) 
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(Chart 44) Relative expression of SLC23A2 gene by gender (male: p=0.002; female: 
p<0.001) 
 
6.2. Relative expression of TP53 gene 
 
 
 
 
 
(Chart 45) Relative expression of TP53 gene (p=0.018) 
(Chart 46) Relative expression of TP53 gene by gender (male: p=0.068; female: p=0.055) 
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6.3. Relative expression of RBP1 gene 
(Chart 47) Relative expression of RBP1 gene (p=0.710) 
(Chart 48) Relative expression of RBP1 gene by gender (male: p=0.662; female: p=0.918) 
6.4. Relative expression of MMP9 gene 
 
 
 
 
 
(Chart 49) Relative expression of MMP9 gene (p=0.021) 
 
 
107 
 
 
 
 
 
 
(Chart 50) Relative expression of MMP9 gene by gender (male: p=0.001; female: 
p=0.012) 
6.5. Relative expression of MMACHC gene 
(Chart 51) Relative expression of MMACHC gene (p=0.793) 
(Chart 52) Relative expression of MMACHC gene by gender (male: p=0.619; female: 
p=0.400) 
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6.6. Relative expression of MMADHC gene 
 
 
 
 
 
(Chart 53) Relative expression of MMADHC gene (p=0.298) 
(Chart 54) Relative expression of MMADHC gene by gender (male: p=0.368; female: 
p=0.536) 
6.7. Relative expression of TMCO1 gene 
(Chart 55) Relative expression of TMCO1 gene (p=0.516) 
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(Chart 56) Relative expression of TMCO1 gene by gender (male: p=0.170; female: 
p=0.917) 
 
6.8. Relative expression of THRA gene 
(Chart 57) Relative expression of THRA gene (p=0.747) 
(Chart 58) Relative expression of THRA gene by gender (male: p=0.750; female: p=0.432) 
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7. Correlation between oxidative stress and gene expressions  
We analysed the correlation between oxidative stress markers 
and gene expression, and only the correlation between the 
expression of SLC23A2 gene and TAS or MDA was 
statistically significant (see graphics below). 
 
7.1. Relative expression of SLC23A2 gene and total antioxidant 
activity 
 
 
(Chart 59) Relative expression of SLC23A2 gene and total antioxidant activity –  
CONTROL GROUP 
 
R = 0.527 
p = 0.014 
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(Chart 60) Relative expression of SLC23A2 gene and total antioxidant activity –  
DM-DR GROUP 
 
 
 
 
(Chart 61) Relative expression of SLC23A2 gene and total antioxidant activity –  
DM+DR GROUP 
 
 
 
 
R = 0.524 
p = 0.009 
R = 0.867 
p = 0.0003 
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7.2. Relative expression of SLC23A2 gene and malondialdehyde 
concentration 
 
 
(Chart 62) Relative expression of SLC23A2 gene and malondialdehyde concentration -  
CONTROL GROUP 
 
 
 
 
(Chart 63) Relative expression of SLC23A2 gene and malondialdehyde concentration –  
DM-DR GROUP 
R = -0.674 
p = 0.001 
R = -0.554 
p = 0.002 
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(Chart 64) Relative expression of SLC23A2 gene and malondialdehyde concentration –  
DM+DR GROUP 
 
 
 
 
 
 
 
 
 
 
 
 
R = -0.651 
p = 0.030 
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DISCUSSION 
 
 
1. About Diabetes Mellitus and the design of this work 
Diabetes mellitus (DM) is a chronic metabolic disorder with devastating 
complications affecting millions of persons worldwide. In fact, DM is now 
considered a global epidemic, affecting more than 400 million people. The 
World Health Organization point to DM as one of the first leading causes of 
death. Moreover, it is a fact that the incidence of DM continues to rise 
steadily (1-6, 120, 121). 
 
In this scenario, the identification of main risk factors accompanying a 
hyperglycemic background, as well as the causative environmental factors 
and lifestyle, will theoretically explain this phenomenon (122). Nonetheless, 
new preventive strategies have to be developed to counteract this pandemic 
disease. The Early Activity in Diabetes trial (ACTID) reported that dietary 
advice could reinforce appropriate glycemic control by preventing a decline 
in self-care in DM2 adult patients. Because of this, the benefits of this 
simple intervention draw attention to the pivotal role of diabetic patient 
education. 
 
A major complication of DM is DR. The diabetic retina is the main 
responsible of the visual loss in the age frame from 20 to 65 years. As a 
consequence of this, the social and economic burden of the disease is 
enormous (123). In fact, proliferative DR and diabetic macular edema are 
the most important ocular complications related to DM. 
 
There is a high prevalence for the development of DM2 in Spain (124-127). 
Also in the Spanish Valencian Community, the incidence of DM2 is high. 
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Because of this, it is critical to address whether or not there can be any 
genetic susceptibility/resistance for the development of these DM 
complications in eyes. 
  
The main goal of present work was to illustrate the molecular and genetic 
aspects of the DR regarding the role of various molecules and candidate 
genes involved in major DR pathogenic mechanisms. Such as apoptosis, 
vascular/neural damage, inflammation, oxidative stress and alterations of the 
extracellular matrix. Also if these can be differentially expressed in DM2 
with (+DR) and without (-DR) retinal affectation, to report gender and age 
distribution of DR incidence and ophthalmic data, which may help in the 
identification of patient at risk, of the disease and visual loss.  
 
In the context of the Valencia Study on Diabetic Retinopathy (VSDR) (51), 
a final sample of 81 participants was selected from the databases to be 
included in this work. Major operative procedures were: 1) interview (to 
register personal and familial data), 2) ophthalmological examination (best 
corrected visual acuity, intraocular pressure, ocular fundus examination, 
and the OCT examination, 3) blood collection in fasting conditions, that 
were centrifuged to obtain three separated aliquots for: a) basic biochemistry, 
b) oxidative stress and a set of molecules (vitamin B12, CRP, total protein 
content and Hcys) c) candidate genes.   
 
The database of the VSDR has been useful to achieve the patient´s 
information as well as to schedule the appointments to better prepare the 
sampling collection, including the analytical procedures for our purposes. 
 
Genes that have been investigated in the present work have been: the 
apoptotic regulator TP53, the vitamin C transporter SLC23A2, the regulator 
of the metalloproteinase 9 (MMP9), the mitochondrial protein involved in 
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vitamin B12 metabolism (MMACHC & MMADHC), the RBP1 gene and 
the TMCO1 gene.   
 
A question that arises was: why these genes and not others? The response is 
that these genes have been chosen after an extensive search of scientific 
literature and previous personal experience of my directors in this work. 
 
As designed, such molecules and genes seem to be ultimately linked with 
DM, as well as DR. Nevertheless, all these, alone or in collaboration with 
other factors might prove to be useful in the development of future 
diagnostic and therapeutic strategies and for better eye care in diabetics. 
Consequently to prevent visual loss, and to contribute to an improvement of 
the patient’s life quality.  
 
In addition to this preface, in this section the results obtained through the 
project will be discussed in a stepwise fashion. 
 
2. Socio-demographic Data 
3. Ophthalmic Results 
4. Classical Biochemistry 
5. Molecular Biochemistry of DR 
7. Genetics of DR 
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2. Socio-demographic data 
Mean age of the total participants in the study was 50 ± 15 years. According 
to the main groups, mean age in the DM2 was 52 ± 6 years versus 47 ± 14 
years in the controls. Attending to gender, 54.3% of total participants were 
men versus 45.7% women. In relation to the gender percentages in the main 
groups: 57.1% men and 42.9% women in the DM2 as well as 50% men and 
50% women in the controls. These data regarding age and gender are similar 
to descriptions from a recent study on DM in a Spanish population (124) 
 
Regarding the DR, data from this study are in agreement, in general, with 
those reported by Salinero-Fort et al., which were also obtained in a Spanish 
population (125). 
 
3. Ophthalmic Results 
According to The American Academy of Ophthalmology screening for DR 
includes the eye dilation and examination of the ocular fundus, as well as 
using validated digital imaging involving 3D retinographies and OCT 
macular data. These approaches have been used herein to address the 
diagnosis and classification stage of DR in the DM2 patients. 
 
Our data showed significantly lower values for the BCVA in each eye in the 
DM2 patients versus the controls, as expected. No statistical differences 
were obtained when data from the IOP and the OCT examination were 
processed. In addition, our results demonstrated significantly reduced BCVA 
and OCT results in macular thickness values in the diabetics’ +DR eyes as 
compared to the control group. This strongly indicates that the retinal images 
are useful enough to manage the diagnosis and subsequent therapy for the 
diabetic eyes, as widely demonstrated (126, 127). 
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The eye care in diabetics includes a medical interview, a standardized 
ophthalmic examination as well as screening of high quality retinal 
photographs of patients who have not had previous treatment for DR, and a 
strict follow-up of these patients. An effective screening program can 
determine who needs a possible treatment, and who simply requires annual 
screening, as recommended (128). 
 
4. Classical Biochemistry 
Previous works have widely described that intensive control of major risk 
factors such as hyperglycemia and hypertension are helpful in reducing the 
onset and progression of DR (125-128). 
 
Higher lipidic profile has been proposed as a risk factor for DR because of 
its relation to endothelial dysfunction playing a role in retinal exudate 
formation in the course of DR (125, 126). Large epidemiological studies 
reached controversial results regarding the association of serum lipids with 
the severity of DR. In the ETDRS report (125), high total cholesterol and 
LDL levels were associated with retinal hard exudates. However, other 
studies failed in demonstrate these conclusions, such as in the Multi-Ethnic 
Study of Atherosclerosis and the Australian Diabetes, Obesity, and Lifestyle 
Study (126). Because of this, in this study, we aimed to investigate whether 
serum lipids have an effect on the development of DR. 
 
Our results confirmed that mean HbA1c values were significantly higher in 
DM2 vs. the control group of participants. Moreover, these values were also 
higher in the DM2 +DR group than in the DM2 -DR and the healthy controls. 
Furthermore, mean total cholesterol, triglyceride, LDL, HDL levels were 
significantly different between specific subgroups (+DR vs. –DR), as can be 
seen in the corresponding tables of the results section.  
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Regarding other parameters, it has been shown that the vitamins B9 and B12 
as well as the Hcys displayed different levels in the diabetics with or without 
retinopathy as compared to the healthy controls. All together these data 
suggest that the above molecules may be presumptive candidate biomarkers 
for the risk of developing and monitoring DR in DM2 patients, in agreement 
with previous reports (51). 
 
Also, our data pointed to HDL and TG significant differences between men 
and women diabetics vs. the controls, which is an interesting point to 
consider for future research regarding gender disparities in the development 
of DR. 
 
In spite of the interesting data from the present work regarding the lipidic 
profile and DR, and the reports of other authors (127, 128) large multi-
centric prospective studies are needed to clarify the reasons of the 
discrepancies reported in distinct studies. 
 
5. Molecular Biochemistry of Diabetic Retinopathy 
DR is a multifactorial disease involving environmental and genetic factors 
(19, 42, 43). This microangiopathy is characterized by abnormal growth and 
leakage of small blood vessels that may result in local edema and functional 
impairment of the retina and choroid. Several mechanisms leading to the 
impairment of microcirculation in diabetes have been implicated, and the 
majority still remains unclear (51-56, 63-67, 125-127).  
 
However, a dysregulated vascular regeneration appears to play a key role. In 
addition, oxidative and hyperosmolar stress, as well as the activation of 
inflammatory pathways triggered by advanced glycation end-products and 
toll-like receptors, increased polyol pathway flux, activation of PKC, etc., 
have been recognized as key underlying events. Therefore, searching for 
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biomarkers of the risk of developing DR is a challenge for researchers 
worldwide. 
 
General strategies for the prevention of DR should be aimed at the 
identification of biomarkers for the risk factors and the main pathological 
mechanisms for better eye care in DM2.  
 
Our work demonstrated the importance of oxidative stress biomarkers for 
DR, in agreement with previous works (51, 63-71). As a consequence of all 
data gathered during the present work, we may suggest that MDA and TAC 
can be useful as biomarkers for the risk of DR in DM2. 
 
6. Genetics of Diabetic Retinopathy 
On the role of genetics of DR, studies reported contradictory findings. 
Genetic susceptibility to DR has also been suggested by some authors. In the 
Veterans Affairs Diabetes Trial, it was described that the prevalence of 
moderate to severe DR was higher for Hispanics and African-Americans 
than for non-Hispanic whites (128). However, ethnicity could not explain by 
itself the differences in the DR prevalence in another population study (127). 
 
Furthermore, no genetic variants meet criteria of useful diagnostic marker; 
neither significantly elucidates the basis of DR development/progression.  
 
Current knowledge of the genetics of DR is quite limited. In spite of the 
strong scientific evidence suggesting that DR is a heritable trait, linkage 
studies, candidate gene association studies and the genome wide association 
study (GWAS) have failed to reveal any reproducible loci for DR (127). 
 
Among the most relevant genes involved in DR are: polyol genes, growth 
factors genes, advanced glycation end products, cytokines genes, 
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transcription factors, etc. Based on these concepts it is necessary to go ahead 
with specific genetics research in DR. In this context, new possibilities and 
approaches associated with utilization of outstanding technologies such as 
the next-generation sequencing or comprehensive read analysis for 
identification of single nucleotide polymorphisms from pooled sequencing 
(CRISP) assays are now available. 
 
Our work is conclusive in respect to the analyzed genes. 
 
TP53, MMP9 and MMACHC/MMADHC genes showed higher expression 
values whereas the SLC23A2 gene exhibited significantly lower values in 
the DM2 patients vs. the controls. In addition, TP53, SLC23A2 and MMP9 
genes showed a differential expression profile in DM2 +DR vs. DM2 –DR. 
 
As previously reported, it can be suggested that genes related to the 
regulation of apoptosis and the integrity of the extracellular matrix, 
altogether with genes involved in the metabolism of antioxidant vitamins 
and cardioprotective/neuroprotective molecules can be involved in the risk 
of developing DR (125). 
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CONCLUSION 
 
 
 
1. The present study confirms the importance of controlling the lipid 
profile in DM2 patients for outstanding diabetic eye care. 
 
2. From a molecular viewpoint regarding DR, the vitamins B9, B12 and 
Hcys are presumptive candidate biomarkers for the risk of developing 
and monitoring DR in DM2 patients. 
 
3. Searching for molecular biomarkers of DR, our data strongly suggest 
that oxidative stress is a relevant pathogenic mechanism. Both the MDA 
and TAC can be utilized as biomarkers of oxidative stress in DM2 
patients at risk of developing DR. 
 
4. Among the eight studied genes, the MMP9 gene may be consider an 
outstanding genetic biomarker of susceptibility to DR. 
 
5. Among the eight studied genes the SLC232A2 can be highly considered 
as a protective factor for the DR development and progression. 
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